Annual Report (10-k)

Date : 05/24/2019 @ 9:47PM
Source : Edgar (US Regulatory)
Stock : Alkame Holdings, Inc. (PN) (ALKM)
Quote : 0.0005  0.0 (0.00%) @ 1:00AM

Annual Report (10-k)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-K

 

[X]

ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

 

For the fiscal year ended December 31, 2016

 

 

[  ]

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT

 

 

 

For the transition period from _________ to ________

 

 

 

Commission file number: 000-55267

 

Alkame Holdings, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada

98-0661455

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

 

 

3651 Lindell Road

Suite D # 356

Las Vegas, Nevada

 

 

89103

(Address of principal executive offices)

(Zip Code)

 

Registrant’s telephone number: (702) 273-9714

 

 


Securities registered under Section 12(b) of the Exchange Act

 

Title of each class

Name of each exchange on which registered

None

not applicable

 

Securities registered under Section 12(g) of the Exchange Act:

 

Title of each class

 

Common Stock, par value $0.001

 

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes [ ] No [X]

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes [ ] No [X]

 

Indicate by checkmark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.          Yes [  ] No [X]

 

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.     [  ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

[      ]

 

Accelerated filer

[      ]

Non-accelerated filer

[      ]

 

Smaller reporting company

[ X  ]

 

 

 

Emerging growth company

[      ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provide pursuant to Section 13(a) of the Exchange Act.   [    ] 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [ ] No [X]

 

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrants most recently completed second fiscal quarter.   $4,400,000

 

Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date: 5,500,000,000 common shares as of May 23, 2019.

 

 

TABLE OF CONTENTS

 

 

 

 

Page

PART I

 

Item 1.

Business

3

Item 1A.

Risk Factors

9

Item 1B.

Unresolved Staff Comments

15

Item 2.

Properties

15

Item 3.

Legal Proceedings

15

Item 4.

Mine Safety Disclosures

 

15

 

PART II

 

Item 5.

Market for Registrant’s Common Equity and Related Stockholder

Matters and Issuer Purchases of Equity Securities

 

16

Item 6.

Selected Financial Data

22

Item 7.

Management’s Discussion and Analysis of Financial Condition

and Results of Operations

23

Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

28

Item 8.

Financial Statements and Supplementary Data

29

Item 9.

Changes In and Disagreements With Accountants on Accounting

and Financial Disclosure

71

Item 9A.

Controls and Procedures

71

Item 9B.

Other Information

72

 

 

 

 

PART III

 

Item 10.

Directors, Executive Officers and Corporate Governance

74

Item 11.

Executive Compensation

 

Item 12.

Security Ownership of Certain Beneficial Owners and Management

and Related Stockholder Matters

75

Item 13.

Certain Relationships and Related Transactions, and Director Independence

76

Item 14.

Principal Accountant Fees and Services

77

 

 

PART IV

 

Item 15.

Exhibits, Financial Statement Schedules

78

 

 


 

 

PART I

Item 1. Business

 

Overview

Alkame Holdings, Inc. is a publicly traded health and wellness technology holding company, with a focus on patentable, innovative, and eco-friendly consumer products utilizing a patented unique water treatment technology. The Company's wholly-owned subsidiaries are diligently pursuing multiple applications to utilize its Intellectual Property by focusing our efforts on several emerging business sectors, such as the prepared and prepackaged food and beverage mixes, the growing aqua-culture industry, consumer food & beverage products, household pet products, horticulture and agriculture, medical, health & beauty, as well as a number of water-based applications to both new and existing business platforms. Our holding company can provide the infrastructure, protective umbrella and transparency of a publicly listed company to acquisition candidates through their incubation and provides the delivery mechanism for these alternative and innovative methods, products, and systems that will lead to healthier lifestyles and result in a more sustainable planet. Our principal executive offices are located at 3651 Lindell Road, Suite D # 356, Las Vegas, Nevada 89103, and our telephone number is (702) 273-9714.

On April 21, 2014, we entered into a Stock Purchase Definitive Agreement (the “Agreement”) with Xtreme Technologies, Inc., an Idaho corporation (“Xtreme”). Pursuant to the terms of the Agreement, we agreed to acquire all of the issued and outstanding capital stock of Xtreme in exchange for certain consideration as set forth in the Agreement.

 

On January 16, 2015, the parties to the Agreement entered into an amendment (the “Amendment”) that changed, among other things, the Closing Date of the transaction.

 

On April 15, 2015, the parties to the Agreement entered into a second amendment (the “Second Amendment”) that changed, among other things, the 120-day time period to pay monetary consideration under the Agreement to 240 days after the Closing Date of the transaction.  

 

In accordance with the terms of the Agreement, the Amendment and the Second Amendment, we agreed to purchase all of the outstanding shares of Xtreme for the purchase price of $2,000,000, payable as follows:

 

A cash payment of $50,000 has been previously paid as a non-refundable deposit; 

The Closing Date is effective as of January 13, 2015; 

An additional cash payment of $525,000 shall be paid within two hundred and forty (240) days of the Closing Date, which, along with the initial $50,000 deposit, shall pay the obligations on Xtreme’s balance sheet;  

The balance of $1,425,000 shall be payable by the issuance of shares of the Company’s Series C Preferred Stock to be divided pro rata among the Company’s shareholders of record as of the Closing Date. The Series C Preferred Stock shall include an option to convert each share of Series C Preferred Stock into one share of the Company’s Common Stock. The Series C Preferred Stock shall be held in escrow along with the issued and outstanding shares of Xtreme’s capital stock pending the full payment of $525,000. As of the date of this report, the balance of $525,000 has been fully paid to Xtreme; and 

One of Xtreme’s previous officers and directors holds outstanding options to purchase up to 1,009,000 shares of Xtreme’s common stock at the price of $0.10 per share. At the Closing Date, pursuant to Idaho law, Xtreme shall notify this previous officer and director of his 30-day right to exercise any or all of his remaining options. If he elects to exercise any of his options within such 30-day period, the Company agrees to issue additional shares of Series B Preferred Stock in exchange for such Xtreme shares.  Xtreme notified the option holder and the 30-day period expired unanswered.  The options expired unexercised. 

 

The Amendment also requires that the Company guarantee the obligations on employment agreements for Xtreme’s key employees, namely, Keith Fuqua, Timm Ott and Casey Henry. The employment agreements with Messrs. Fuqua, Ott and Henry have the terms set forth in the following table.

 

3

Employee

Position

Term

Compensation

Commission

Benefits

Severance

Keith Fuqua

Operations Director

One year

$70,000 annually and annual bonus

5% on gross sales made to Walmart

Benefit plans

6 months’ severance for termination in certain instances; residual commissions for 1 year

Timm Ott

Sales and Marketing Director and Treasurer

One year

$2,700 per month salary and annual bonus

$1.00 per case of product sold

Benefit plans

6 months’ severance for termination in certain instances

Casey Henry

Manufacturing Director

One year

$4,350 per month and annual bonus

$1.00 per case of product sold

Benefit plans

6 months’ severance for termination in certain instances

 

In addition, after the Closing Date, Xtreme’s current officers and directors, namely, Jeffery J. Crandall, John N. Marcheso and Michael J. Bibin, shall continue to serve in that capacity until the $525,000 is paid in full. Our President and CEO, Robert K. Eakle and two (2) additional representatives of our company shall be appointed as directors of Xtreme and shall serve together with the other directors until the $525,000 is paid in full. In addition, Mr. Eakle shall be named as President and Chief Executive Officer of Xtreme. Until the $525,000 is paid in full, the officers and directors of Xtreme shall not make any material change in the company’s business and operations without unanimous consent of the directors. By January 2017, the $525,000 was fully paid and the appointments of Mr. Eakle and the other two representatives as interim officers and directors became permanent. Prior to completion of the payment of $525,000 in full to Xtreme, all former officers and directors of Xtreme had resigned and full control of Xtreme was be tendered to us. Given that certain representations were accurate, Jeffery J. Crandall, John N. Marcheso and Michael J. Bibin were released by us and Xtreme from any liability as officers and directors of Xtreme for their fiduciary obligations occurring prior to the Closing Date.

 

We previously held a three-year limited exclusive distribution agreement with Xtreme for the consumer market. We were permitted to distribute the technologically enhanced bottled water in the consumer market in the United States, Canada and Mexico. As a result of the Agreement, Amendment, and Second Amendment, Xtreme became our wholly-owned subsidiary and we acquired the patents on the proprietary process that we believe is the most technologically advanced in water treatment systems for complete hydration. We will now assume the operations of Xtreme and continue its business of distributing technologically enhanced bottled water.

 

Upon closing of the acquisition, we discovered that Xtreme was operating at a loss for the prior year and that it required a substantial cash infusion.  We began a program of upgrading the production line, reorganized personnel, and began an effort to increase sales of the division so that it would return to profitability as quickly as possible.  However, as 2015 progressed, it became obvious that changes in contracts negotiated prior to our acquisition were no longer profitable and we terminated the agreements with those customers.  In mid-2017, the Company determined that Xtreme was no longer an asset as an operating company and closed the facility and moved the operations to a new location in the state of Oregon.  

Our primary objective now is to introduce, promote, aggressively market and establish channels of distribution to sell a variety of products to a wide range of consumers and business sectors, first in the United States, Canada and Mexico, and then globally.  In addition, the Company is moving in the direction of bottling or “co-packing”.  To that end, the Company, in 2017 moved to Oregon and started a new subsidiary, Bell Food and Beverage, Inc., for the production of “hot pack” foods and beverages and relocated all of its production equipment and inventory to the same location from which it now operates.

We believe that holding the acquired patents provide a competitive edge in the water treatment market, allowing us to expand our reach in the distribution of water and other complementary products, and enables us to enhance our position in the investment community.

 

4


Our Water Product

With the public becoming more aware of the benefits of a “living water”. The mild alkalinity of Alkame is recommended by numerous athletes and doctors because it’s formulated for more effective hydration by supporting an optimal pH balanced water. Alkame water is produced with a patented technology and patented formula that alters the structure of water, producing a combination of unique characteristics.

Today our water is pumped from wells that tap into the Columbia aquifer, located in the heart of the Willamette Valley in Oregon. Our water is not treated with chlorine, fluorides, or any other harmful contaminants. This source water is then run through up to 14 different filters, reverse osmosis, and UV to remove any particulates and harmful contaminants, rendering a pure, clean, healthier water which can then be used as a base for multiple applications.  We believe our water advances beyond other brands once we introduce the technology, which includes manipulation of the pH levels, structure size, ionization, as well as an increased bioavailable oxygen content. This proprietary system creates a unique micro-clustered alkaline water, providing additional health benefits.

Alkame Water, our flagship brand and water product, was developed as a vehicle to get the word out about the technology, and that it can be applied across a diverse and wide-ranging spectrum of businesses and water-based applications. Alkame Water started with 3 phases of initial bottled water products and has currently completed 2 of these 3 Phases.  1 was to develop the initial move into the consumer market consisting of half liter and one-liter bottles. Phase 2 was the development of new packaging configurations and an increased offering with a full range of sizes to boost the cross marketability, co-branding, and private label options for our products. In phase 2 we rounded out our product lines to now consist of 16.9oz, 20oz, 33.8oz, 50.7oz, 128oz, 135.25oz configurations. Phase 3 has been updated and corrected to reflect the true direction of this unique water brand, how it can be applied to a larger multitude of products and various business sectors. Today we are focused on the development and expansion of its utilization in multiple products through co-packing and private label business, as well as expanding the distribution footprint of the Alkame brand and its technologically superior water technology.

The Benefits of the Technology

The Alkame Technology has proven benefits that go way beyond just being “wet”, which is why we trademarked the tagline “The Ultimate Health & Wellness Water”.  Our advanced hydration technology is advancing us into other market segments outside of the bottled water consumer markets. Our system will process, clean, and reduce water, lower its TDS (total dissolved solids), increase its pH, provide antioxidant protection, and increase the amount of bio-available oxygen. We believe Alkame is the only product of its kind and stands completely apart from other “waters”.

Alkame Water has an elevated level of dissolved oxygen and lower oxidation reduction potential (ORP) due to passage through an electrolytic cell and has a level of dissolved oxygen additionally elevated due to passage through a sparging unit comprising of 1) dissolved oxygen within the range of 20 to 60 parts per million and 2) an ORP between +100 to -350mV (micro-clustered), and coupled with a pH level averaging 8 to 8.5pH (alkaline).

The Alkame Technology helps support an optimum pH balance and reduce the negative impact of acid in the body, provide antioxidant protection from this energy-robbing oxidative damage, and effectively maximize blood oxygen levels with an efficient delivery mechanism to every part of your body allowing for a more complete hydration, especially when that is coupled with electrolyte and other form of enhancements. Maximized blood oxygen levels mean improved metabolic efficiency, which translates into more energy and improved vitality. If you wish to overcome fatigue and boost energy, it is essential that you achieve and maintain optimal hydration. By maximizing your blood oxygen saturation, and an alkaline pH, and antioxidant support, you can improve digestion, metabolic function, immune response, and healing. Supporting an efficient metabolism will help you maintain the level of energy and vitality desired. When free radicals become too numerous, they become highly destructive, damaging cells and tissue of muscles and vital organs. If your body’s processes are impaired, the first place you start to feel the effects is in your vitality and energy levels. Alkame is a powerful source, which boosts the immune system, improves aerobic capacity, is good for overall health, and enhances energy and overall vitality.

 

5


Today, we are employing our technology to multiple companies across a diverse spectrum of applications in the consumer market segment. To continue our cross-marketing efforts, there has been a wide array of products being released into the market by our manufacturing subsidiaries, co-branded with a “Powered by Alkame Technology” icon. This has helped us both further our reach, as well as enable more people to enjoy the benefits of our technology.  

The Market

 

With the massive influx of new eco-friendly products, consumers are going green, both externally as well as internally. The “well-being” generation and others have become increasingly aware of what they are consuming, and this new technology for water treatment is quite the prized possession for those looking to optimize their health.  Our ability to incorporate other elements from electrolytes to supplements including hemp is where we believe we’ll see expansion over the next few years. We expect Alkame to be a significantly improved delivery mechanism due to its micro-clustered structure. The market for these types of products are gaining traction and becoming synonymous with good health and proper hydration, and we intend to be the first household technology name for superior products utilizing this type of water treatment technology.

The market for this technology is expansive since there are so many products and businesses that utilize water and water treatment technology in one form or another. We have driven into the human and household pet sectors, with brands we created, co-branded products, and private label business. The hemp space is huge, and we are one of the top production houses for manufacturing these types of products. We delved into the aquaculture market with a lot of scientific research on the efficacy of this application, which looks very promising. We recently received our aquaculture license from the state of Oregon and are looking to have a small active fish farm to be utilized as a proof of concept to show large format producers for the scalability of the technology and its introduction into the aquaculture sector. We are now exploring medical applications which also look very promising.

Beginning in 2017, we began making some very strategic moves behind the scenes to position ourselves as the wheel house and primary incubator for both new and emerging product and brand development. Our move to Oregon, and the added influx of capabilities and options, are really the driving factor in the success we are seeing now. As the manufacturer, our ability to create brands and products for both ourselves and others really creates an almost limitless amount of opportunities in a multitude of markets and sectors. We are seeing expansion on all fronts because of this strong move towards expanding the production capabilities. Our ability to get hemp-based products through both the state process authorities as well as the FDA makes us a force to be reckoned with in today’s markets.

Competition and Feasibility

The Company competes on the basis of product quality and customer service. The Company believes that the products' Alkaline, Antioxidant and Oxygenated features, along with its superior taste, and attractive packaging options are significant factors in maintaining the Company's competitive position. We believe we have a superior product with more features and sell on the benefits and functions, not the price. We believe our ability to incorporate additional supplemental materials using this water as the base can provide a more efficient delivery mechanism, has enabled us to exploit this technology by offering it to others to be utilized in their products. Co-branding with the “Powered by Alkame Technology” enables us to continue to utilize all of these products as vehicles to get the word out about the technology, and not solely on our brand alone. Since we have repositioned ourselves as the production house, the competition dynamic changes dramatically in our favor.

Experiments on the Technology

The technology for alkaline bottled water has undergone separate double-blind placebo, peer backed research. One was with HIV patients and the other was on Exercise Tolerance. The feasibility of the product is clearly evident, and we believe there is no major competition to date.

 

6


Based on the study with HIV patients undergoing antiretroviral therapy it was concluded that drinking sufficient quantities of Alkame water improves important parameters of health in individuals infected with HIV. Drinking Alkame provides a significant boost to the immune system as shown by an increase in CD4 T cells (which are the primary targets of HIV and are crucial for immune defense against infections) and a decrease in the total virus load of HIV patients.

Based on the Exercise Tolerance study, the amount and the type of water consumed during rehab revealed a difference in the patient’s aerobic endurance. We found that drinking one liter of electrolyzed alkaline water is more beneficial than drinking three liters of plain water, which is great news for chronic obstructive pulmonary disease patients with congestive heart failure. In light of our study, Kern Rehab henceforth furnishes one liter of electrolyzed alkaline water for each patient participating in our comprehensive outpatient pulmonary rehab facility. The reason being, 3 liters of plain water per day exhibited 12.4% MET improvement in the exercise and fitness level per 6-minute walk /12-week program, whereas, 1-liter of electrolyzed alkaline water exhibited 17.8% MET improvement.

Effects of Alkame Water on blood lactate following exercise in a recent double-blind study conducted by Athletic Lab in North Carolina, under the supervision of Mike Young provided scientific evidence that Alkame Water will lower lactic acid accumulation during repetitive sprints/ interval training. Blood lactate was taken before and after the conclusion of the sprints using a Lactate Plus monitor from Nova Biomedical under a standardized warm up and exercise protocol.  Results of the T-tests showed that hydrating your workout with Alkame water lowers maximum exercise heart rate and lactic acid accumulation during repetitive sprints/ interval training. Less fatigue, quicker recovery between intervals and less soreness after your workouts means you'll be training hard, longer while staying hydrated.

Outside of the effects on consumers, the company also tested the water treatment technology in aquaculture fish farming by studying its effects on Tilapia specifically. The major advantage of Alkame technology is that it can completely or partially destroy organics in water by converting them into various harmless intermediates and end products. Alkame’s advanced system and design ensures that high concentrations of dissolved oxidants are released to the water when circulated across the cells, reducing Nitrites by 50%. Clarity and solids were also substantially reduced from 4 inches to over 20 inches after oxidation within 48 hours. Tannins and Lignin’s from feed leaching were removed with the Alkame process along with organic solids creating clearer and healthier water conditions. These factors could substantially reduce the size and costs of bio-filtration design for intensive recirculation systems. Our studies show that the Alkame Technology aids in the overall health of the water, which in turn creates a healthier environment to raise the fish. The Tilapia benefit by lowering the mortality rate (less than 2% mortality), accelerating growth (1 gram to about 38 to 50 grams in less than 60 days), and by reducing the size and cost to the bottom line of bio-filtration efficiency. Producing a cleaner healthier water for the Tilapia is a game changer for Aquaculture systems, and the industry worldwide.  

Sales and Marketing

 

Originally, our primary focus was on exposing the product and building brand name recognition and technology awareness through Alkame’s utilization of celebrity and athletic ambassadors, cross-marketing and co-branding, and via sponsorships of key existing and potential clients (mostly in the health & wellness fields and athletic markets). A special and unique emphasis is placed on action sports to build on its cool factor. Although these techniques did not directly translate into sales and distribution, the utilization of mass media and celebrity endorsement provided our sales teams with the most essential marketing and sales tools and support needed to move product to distributors, as well as drive it through three main channels of on premise, off-premise, and special events.

 

Advertising, public relations and promotions are the life blood of any company and by far one of our strongest attributes. As we developed new product lines, the icons associated with our new products and brand trademarks was used consistently and accurately to achieve the goal we set. How we visually communicated our product to the world, the market, and our potential clients was an integral part of the success we are seeing now. Consistent usage of style and identity gave the world an impression that can be easily remembered through these various media and materials such as product placement, endorsements, sponsorships, advertorials and editorials, advertisements, marketing collateral, signage, the web, etc. Current trends and new marketing techniques utilizing out of the box thinking, and targeted promotional strategies to increase publicity and public relations awareness has been an essential tool for us,

 

7


along with the high level of service we use in marketing our products and services to our customers. The combined concentration of expertise and experience of the Alkame team is the key to giving us a real shot at being able to compete with the biggest players in the industry. The other key component, and by far the most invaluable to our success, is our customers. With the rapidly growing awareness of health and longevity, Alkame is a perfect fit.

 

Governmental Regulation

 

The Federal Food and Drug Administration (FDA) regulates bottled water as a “food.” Accordingly, our bottled water must meet, and we do meet FDA requirements of safety for human consumption, of processing and distribution under sanitary conditions and of production in accordance with the FDA “good manufacturing practices.” To assure the safety of bottled water, the FDA has established quality standards that address the substances that may be present in water which may be harmful to human health as well as substances that affect the smell, color and taste of water. These quality standards also require public notification whenever the microbiological, physical, chemical or radiological quality of bottled water falls below standard. The labels affixed to bottles and other packaging of the water is subject to FDA restrictions on health and nutritional claims for foods under the Fair Packaging and Labeling Act. In addition, all drinking water must meet Environmental Protection Agency standards established under the Safe Drinking Water Act for mineral and chemical concentration and drinking water quality and treatment that are enforced by the FDA.

 

We are subject to the food labeling regulations required by the Nutritional Labeling and Education Act of 1990. We believe we are in compliance with these regulations.

 

We are subject to periodic, unannounced inspections by the FDA. Upon inspection, we must be in compliance with all aspects of the quality standards and good manufacturing practices for bottled water, the Fair Packaging and Labeling Act, and all other applicable regulations that are incorporated in the FDA quality standards. We believe that we meet the current regulations of the FDA. All of our plants and distribution locations are registered with the FDA under the "Public Health Security and Bioterrorism Preparedness and Response Act of 2002". Most recently, the FDA put into effect the Bottled Water Microbial Rule to monitor water sources for E. coli bacteria. We have been in compliance with the testing requirements for this rule prior to and since its inception in December 2009.

 

We also must meet state regulations in a variety of areas to comply with purity, safety, and labeling standards. From time to time, our facilities and sources are inspected by various state departments and authorities.

 

Our product labels are subject to state regulation (in addition to federal requirements) in each state where the water products are sold. These regulations set standards for the information that must be provided and the basis on which any therapeutic claims for water may be made.

 

In recent years, there has been an increasing amount of proposed legislative and executive action in state and local governments that would ban the use of bottled water in municipal buildings, enact local taxes on bottled water, and limit the sale by municipalities of water supplies to private companies for resale. Such regulation could adversely affect our business and financial results. For additional information, see “Risk Factors” below.

 

The laws that regulate our activities and properties are subject to change. As a result, there can be no assurance that additional or more stringent requirements will not be imposed on our operations in the future. Although we believe that our water supply, products and bottling facilities are in substantial compliance with all applicable governmental regulations, failure to comply with such laws and regulations could have a material adverse effect on our business.

 

Other Applications

 

We are exploring other uses of our water so that we can diversify our portfolio of products to include other specialty uses outside of the bottled water and health water markets.

Employees

We currently are working with various independent consultants and sales representatives, with a total infrastructure of approximately 25 people.

 

8


Item 1A. Risk Factors

The following are certain identifiable risk factors for our business operations.

Because our auditor has issued a going concern opinion regarding our company, there is an increased risk associated with an investment in our company.

 

We have earned nominal revenue since our inception, which makes it difficult to evaluate whether we will operate profitably. We have an accumulated deficit of $14,900,121 and have incurred a net loss of $1,921,865 for the year ended December 31, 2016.  We have not attained profitable operations and are dependent upon obtaining financing or generating revenue from operations to continue operations for the next twelve months. As of December 31, 2016, we had -$0- cash on hand, which is insufficient for operations during the next 12 months. Our future is dependent upon our ability to obtain financing or upon future profitable operations. We reserve the right to seek additional funds through private placements of our common stock and/or through debt financing. Our ability to raise additional financing is unknown. We do not have any formal commitments or arrangements for the advancement or loan of funds. For these reasons, our auditors stated in their report that they have substantial doubt we will be able to continue as a going concern. As a result, there is an increased risk that you could lose the entire amount of your investment in our company.

 

We have substantial indebtedness.  The amount of our outstanding indebtedness continues to increase and our ability to make payments towards such indebtedness could have adverse consequences on future operations.

 

Our outstanding indebtedness at December 31, 2016 was $3,209,353, which was comprised of a variety of short-term and long-term borrowings; convertible debentures; accounts payable; accrued expenses and interest; and related party loans.  The level of indebtedness we have affects our operations in a number of ways.  We will need to use a portion of our cash flow to pay principal and interest and meet payables commitments, which will reduce the amount of funds we will have available to finance our operations.  This lack of funds could limit our flexibility in planning for or reacting to changes in our business and the industry in which we operate and could limit our ability to make funds available for other purposes, such as inventory purchases, payroll, development or acquisition activities.  Our ability to meet our debt service obligations and reduce our total indebtedness will depend upon our future performance.  Our future performance, in turn, is dependent upon many factors that are beyond our control such as general economic, financial and business conditions.  We cannot guarantee that our future performance will not be adversely affected by such economic conditions and financial, business and other factors.

 

Our failure to raise additional capital or generate cash flows necessary to expand our operations could reduce our ability to compete successfully and adversely affect our results of operations.

 

We may need to raise additional funds to achieve our future strategic objectives, and we may not be able to obtain additional debt or equity financing on favorable terms, if at all. If we raise additional equity financing, our security holders may experience significant dilution of their ownership interests and the value of shares of our common stock could decline. If we engage in debt financing, we may be required to accept terms that restrict our ability to incur additional indebtedness, force us to maintain specified liquidity or other ratios or restrict our ability to pay dividends or make acquisitions. If we need additional capital and cannot raise it on acceptable terms, we may not be able to, among other things:

 

• develop and enhance our existing products and services;

• continue to expand our operations;

• hire, train and retain employees; or

• respond to competitive pressures or unanticipated working capital requirements.

 

Our inability to do any of the foregoing could reduce our ability to compete successfully and adversely affect our results of operations.

 

 

9


Because we have a limited operating history related to our current business strategy, we are subject to the risks of failure associated with any new business ventures.

 

We have a limited operating history related to our current business strategy on which potential investors can assess our performance and prospects. Potential investors should be aware that there is a substantial risk of failure associated with any new business strategy as a result of problems encountered in connection with their commencement of new operations. These include, but are not limited to, the entry of new competition, unknown or unexpected additional costs, and expenses that may exceed estimates.

 

Our failure to maintain adequate internal controls over our financial and management systems have caused errors in our financial reporting. These errors may cause a loss of investor confidence and result in a decline in the price of our common stock.

 

Beginning in early 2016, the Company became delinquent in its filing obligations due to cash constraints on our business.  This report and the remaining filings that are due will be completed in the coming months.  Their late filings show that until recently our financial status and reporting was insufficient to meet the reporting requirements.  These issues have now been addressed and we expect continued improvement in our reporting obligations as we have added 2 persons to the accounting staff, and in the process of improving our systems to complete our reporting in a timely manner.

 

In addition, pursuant to Section 404 of SOX, and the Jumpstart Our Business Startups Act, or JOBS Act, we are required to provide annually an assessment of the effectiveness of our internal controls over financial reporting and, starting with the year after we are no longer an “emerging growth company” as defined in the JOBS Act, our independent registered public accounting firm will be required to provide an attestation on our assessment of our internal controls over financial reporting.

 

The process required to comply with Section 404 of SOX is time consuming and costly. If during this process we identify one or more material weaknesses in our internal controls, it is possible that our management may not be able to certify that our internal controls are effective by the certification deadline.

 

Moreover, if we identify any material weaknesses or significant deficiencies in our internal controls we will have to implement appropriate changes to these controls, which may require specific compliance training for our directors, officers and employees, require the hiring of additional finance, accounting, legal and other personnel, entail substantial costs to modify our existing accounting systems and take a significant period of time to complete. Such changes may not, however, be effective in maintaining the adequacy of our internal controls, and any failure to maintain that adequacy, or consequent inability to produce accurate financial statements on a timely basis, could increase our operating costs and could materially impair our ability to operate our business. Effective internal controls are necessary for us to produce reliable financial reports and are important to prevent fraud. As a result, our failure to satisfy the requirements of Section 404 on a timely basis could result in us being subject to regulatory action and a loss of investor confidence in the reliability of our financial statements, both of which in turn could cause the market value of our common stock to decline.

 

Because we have a claimant that believe he is entitled to millions of shares in our company, our shareholders may be subject to significant dilution.

 

In May 2014, we received notice that a complaint was filed in District Court, Clark County, NV alleging that our company and various unnamed defendants are liable to a Mr. Renard Wiggins with regard to commissions and equity purportedly owed Mr. Wiggins, for services allegedly rendered in raising capital on our behalf prior to the reverse merger between Pinacle Enterprises Inc. (now Alkame Holdings, Inc.) and Alkame Water, Inc. in September 2013. After initial review, we have filed for a dismissal of the case with the District Court, do not believe there is any validity to the claims of Mr. Wiggins, and intend to vigorously continue defending against these claims. To date, all but two claims have been dismissed, and we are in court mandated settlement talks to determine if the remaining counts can be dismissed or will require further litigation.  

 

In early 2017, the Company entered into a stipulated settlement agreement to issue 200,000,000 common shares in full and final settlement of this matter and all legal complaints are withdrawn.  In June 2018, the Company issued 92,780,388 shares of the agreed upon settlement.

 

10


 

We depend upon maintaining the integrity of our water sources and manufacturing process. If our water sources or bottling processes were contaminated for any reason, our business would be seriously harmed.

 

Our ability to retain customers and the goodwill associated with our brands is dependent upon our ability to maintain the integrity of our water resources and to guard against defects in, or tampering with, our manufacturing process. The loss of integrity in our water sources or manufacturing process could lead to product recalls and/or customer illnesses that could materially adversely affect our goodwill, market share and revenues. Because we rely upon natural spring sites for sourcing some of our water supply, acts of God, such as earthquakes, could alter the geologic formation of the spring sites, constricting or even contaminating water flow.

 

Because our business is dependent upon the performance of key employees, the loss of those employees would materially impact our business.

 

Our business is dependent upon the performance of certain key employees. Competition for these individuals is intense and many of our key employees are at-will employees who are under no legal obligation to remain with us. Our competitors may choose to extend offers to any of these individuals on terms which we may be unwilling to meet. In addition, any or all of our key employees may decide to leave for a variety of personal or other reasons beyond our control.

 

Also, our business depends upon the continued efforts, abilities and expertise of our officer and director, Robert Eakle. We believe that the unique combination of skills and experience he possesses would be difficult to replace, and his loss could have a material adverse effect on us, including impairing our ability to execute our business strategy. We have a one-year written employment agreement with Mr. Eakle. This furthers the risk that we will not be able to secure his services on a long-term basis. If we lose the services of Mr. Eakle our business will suffer.

 

We face competition from companies with far greater resources than we have. In addition, methods of competition in the distribution of home and office refreshment products continue to change and evolve. If we are unable to meet these changes, our business could be harmed.

 

We operate in highly competitive markets. The principal methods of competition in the markets in which we compete are distribution capabilities, brand recognition, quality, reputation, and price. We have a significant number of competitors in our traditional water market, some of which have far greater resources than us. Among our principal competitors are Nestlé Waters North America, large regional brands owned by private groups, and local competitors in the markets that we serve. Price reductions and the introduction of new products by our competitors can adversely affect our revenues, gross margins, and profits.

 

The bottled water industry is regulated at both the state and federal level. If we are unable to continue to comply with applicable regulations and standards in any jurisdiction, we might not be able to sell our products in that jurisdiction, and our business could be seriously harmed.

 

The FDA regulates bottled water as a food. Our bottled water must meet FDA requirements of safety for human consumption, labeling, processing and distribution under sanitary conditions and production in accordance with FDA “good manufacturing practices.” In addition, all drinking water must meet Environmental Protection Agency standards established under the Safe Drinking Water Act for mineral and chemical concentration and drinking water quality and treatment, which are enforced by the FDA. We also must meet state regulations in a variety of areas. These regulations set standards for approved water sources and the information that must be provided and the basis on which any therapeutic claims for water may be made. We have received approval for our drinking water in Idaho and Nevada. However, we can give no assurance that we will receive such approvals in the future.

 

11


Changes in laws and regulations relating to beverage containers and packaging could increase our costs and reduce demand for our products.

We intend to offer non-refillable, recyclable containers in the United States. Legal requirements have been enacted in various jurisdictions in the United States and overseas requiring that deposits or certain ecotaxes or fees be charged for the sale, marketing and use of certain non-refillable beverage containers. Other proposals relating to beverage container deposits, recycling, ecotax and/or product stewardship have been introduced in various jurisdictions in the United States and overseas, and we anticipate that similar legislation or regulations may be proposed in the future at local, state and federal levels, both in the United States and elsewhere. Consumers’ increased concerns and changing attitudes about solid waste streams and environmental responsibility and related publicity could result in the adoption of such legislation or regulations. If these types of requirements are adopted and implemented on a large scale in any of the markets in which we operate, they could affect our costs or require changes in our distribution model, which could negatively impact our financial condition. In addition, container-deposit laws, or regulations that impose additional burdens on retailers, could cause a shift away from our products to retailer-proprietary brands, which could impact the demand for our products in the affected markets. Fluctuations in the cost of essential raw materials and commodities, including fuel costs, for the manufacture and delivery of our products could significantly impact our business.

Bottle manufacturers use plastic and other petroleum-based products for the manufacturing of our bottles. Increases in the cost of petroleum will likely have an impact on our bottle costs.

We rely on trucking to receive raw materials and transport and deliver our finished products. Consequently, the price of fuel significantly impacts the cost of our products. Limitations on the supply or availability of fuel could inhibit our ability to get raw materials and distribute our products, which in turn could have an adverse effect on our business.

If we are unable to succeed in marketing, making sales and increasing our customer base to support our business operations, we will be unable to achieve profitable operations, and our business may fail.

 

If we are unable to succeed in marketing, making sales and expanding our customer base to support our business operations, any adverse change by any of our larger volume customers could be detrimental to our profitability. Numerous factors beyond our control may affect the marketability of the products offered. These factors include, but are not limited to, consumer demand and emerging competition. The exact effect of these factors cannot be accurately predicted, but it is possible they may result in our not receiving an adequate return on our invested capital.

 

Because we are dependent on third parties, should those services be interrupted or become more costly, we may experience a material adverse effect on the acceptance of our brand and on our business, financial condition, and operating results.

 

There is risk of change in the types of products being manufactured, and our ability to acquire the best products from our suppliers. Because we are dependent on third parties, especially product manufacturers and distributors, we face potential losses if any of these products are interrupted or become more costly. Additionally, any failure on the part of these partners, upon whom we may rely to supply us with products and services, will reflect poorly upon our brand, and therefore result in reduced revenue.

 

If we are unable to successfully manage growth, our operations could be adversely affected.

 

Our progress is expected to require the full utilization of our management, financial and other resources, which to date has occurred with limited working capital. Our ability to manage growth effectively will depend on our ability to improve and expand operations, including our financial and management information systems, and to recruit, train and manage sales personnel. There can be no absolute assurance that management will be able to manage growth effectively.

 

12


If we do not properly manage the growth of our business, we may experience significant strains on our management and operations and disruptions in our business. Various risks arise when companies and industries grow quickly. If our business or industry grows too quickly, our ability to meet customer demand in a timely and efficient manner could be challenged. We may also experience development delays as we seek to meet increased demand for our products. Our failure to properly manage the growth that we or our industry might experience could negatively impact our ability to execute on our operating plan and, accordingly, could have an adverse impact on our business, our cash flow and results of operations, and our reputation with our current or potential customers.

 

If our products are found to cause injury, have defects, or fail to meet industry standards, we will incur substantial litigation, judgment, product liability, and product recall costs, which will increase our losses and negatively affect our brand name reputation and product sales.

 

Defects may be found in our products. Any such defects could cause us to incur significant return and exchange costs, re-engineering costs, divert the attention of our engineering personnel from product development efforts, and cause significant customer relations and business reputation problems. Any such defects could force us to undertake a product recall program, which could cause us to incur significant expenses and could harm our reputation and that of our products. If we deliver products with defects, our credibility and the market acceptance and sales of our products could be harmed.

 

Moreover, we may be subject to liability for any accidents or injury that may occur in connection with the use of our products. We believe we are adequately insured in the event such claims are brought. If we are unable to obtain such insurance, product liability claims could adversely affect our brand name reputation, revenues and ultimately lead to losses. The occurrence of any claims, judgments, or product recalls will negatively affect our brand name image and product sales, as well as lead to additional costs.

 

Our commercial success depends significantly on our ability to develop and commercialize our potential products without infringing the intellectual property rights of third parties.

 

Our commercial success will depend, in part, on operating our business without infringing the patents or proprietary rights of third parties. Third parties that believe we are infringing on their rights could bring actions against us claiming damages and seeking to enjoin the development, marketing and distribution of our products. If we become involved in any litigation, it could consume a substantial portion of our resources, regardless of the outcome of the litigation. If any of these actions are successful, we could be required to pay damages and/or to obtain a license to continue to develop or market our products, in which case we may be required to pay substantial royalties. However, any such license may not be available on terms acceptable to us or at all. Ultimately, we could be prevented from commercializing a product or forced to cease some aspect of our business operations as a result of patent infringement claims, which would harm our business.

 

Because the industry is dependent upon general economic conditions and uncertainties, future developments could result in a material adverse effect on our business.

 

US trade & industry is subject to economic changes and periodical fluctuations. Prolonged declines in the economy and/or a recession could have a material adverse effect on our business. The national economy is affected by numerous factors and conditions, all of which are beyond our control, including (a) Interest rates; (b) Inflation; (c) Employment levels; (d) Changes in disposable income; (e) Financing availability; (f) Federal and state income tax policies; and (g) Consumer confidence.

 

Because our articles of incorporation and bylaws and Nevada law limit the liability of our officers, directors, and others, shareholders may have no recourse for acts performed in good faith.

Under our articles of incorporation, bylaws and Nevada law, each of our officers, directors, employees, attorneys, accountants and agents are not liable to us or the shareholders for any acts they perform in good faith, or for any non-action or failure to act, except for acts of fraud, willful misconduct or gross negligence. Our articles and bylaws provide that we will indemnify each of our officers, directors, employees, attorneys, accountants and agents from any claim, loss, cost, damage liability and expense by reason of any act undertaken or omitted to be undertaken by them, unless the act performed or omitted to be performed constitutes fraud, willful misconduct or gross negligence.

 

13


New legislation, including the Sarbanes-Oxley Act of 2002, may make it more difficult for us to retain or attract officers and directors.

 

The Sarbanes-Oxley Act of 2002 was enacted in response to public concerns regarding corporate accountability in connection with recent accounting scandals. The stated goals of the Sarbanes-Oxley Act are to increase corporate responsibility, to provide for enhanced penalties for accounting and auditing improprieties at publicly traded companies, and to protect investors by improving the accuracy and reliability of corporate disclosures pursuant to the securities laws. The Sarbanes-Oxley Act generally applies to all companies that file or are required to file periodic reports with the SEC, under the Securities Exchange Act of 1934. As a public company, we are required to comply with the Sarbanes-Oxley Act. The enactment of the Sarbanes-Oxley Act of 2002 has resulted in a series of rules and regulations by the SEC that increase responsibilities and liabilities of directors and executive officers. The perceived increased personal risk associated with these recent changes may deter qualified individuals from accepting these roles. As a result, it may be more difficult for us to attract and retain qualified persons to serve on our board of directors or as executive officers. We continue to evaluate and monitor developments with respect to these rules, and we cannot predict or estimate the amount of additional costs we may incur or the timing of such costs.

 

There is currently a limited public market for our common stock. Failure to develop or maintain a trading market could negatively affect its value and make it difficult or impossible for you to sell your shares.

 

There has been a limited public market for our common stock and an active public market for our common stock may not develop. Failure to develop or maintain an active trading market could make it difficult for you to sell your shares or recover any part of your investment in us should you decide to convert all or some of your investment. Even if a market for our common stock does develop, the market price of our common stock may be highly volatile. In addition to the uncertainties relating to future operating performance and the profitability of operations, factors such as variations in interim financial results or various, as yet unpredictable, factors, many of which are beyond our control, may have a negative effect on the market price of our common stock.

 

Because the payment of dividends is at the discretion of the Board of Directors, investors may not realize cash dividends at the frequency or in the amounts they anticipate.

 

We have never declared or paid any cash dividends on our Common Stock. Our payment of any future dividends will be at the discretion of our board of directors after taking into account various factors, including but not limited to our financial condition, operating results, cash needs, growth plans and the terms of any credit agreements that we may be a party to at the time. Distributions to our stockholders are subordinate to the payment of our debts and obligations. If we have insufficient funds to pay our debts and obligations, distributions to stockholders will be suspended pending the payment of such debts and obligations. Accordingly, investors must rely on sales of their own Common Stock after price appreciation, which may never occur, as the only way to recover their initial investment.

 

Rules of the Securities and Exchange Commission concerning low priced securities may limit the ability of shareholders to sell their shares

Our common stock is subject to Rule 15g-9 of the Securities and Exchange Commission which regulates broker/dealer practices in connection with transactions in "penny stocks". Penny stocks generally are equity securities with a price of less than $5.00, other than securities registered on certain national securities exchanges or quoted on the NASDAQ system, provided that current price and volume information with respect to transactions in that security are provided by the exchange or system. The penny stock rules require a broker/dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document prepared by the Commission that provides information about penny stocks and the nature and level or risks in the penny stock market. The broker/dealer also must provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker/dealer and its salesperson in the transaction, and if the broker/dealer is the sole market-maker, the broker/dealer must disclose this fact and the broker/dealers presumed control over the market. This information must be provided to the customer orally or in writing before or with the written confirmation of trade sent to the customer. The bid and offer quotations, and the broker/dealer and its salesperson compensation information, must be given to the customer in writing before or with the customer's confirmation. The broker/dealer must make a special suitability determination

14


for purchasers of the securities and receive the purchaser's written agreement to the transaction prior to sale. Monthly statements must be sent by the broker/dealer to the customer disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks. These disclosure requirements may reduce the level of trading activity in the market for our common stock and may limit the ability of investors in this offering to sell our common stock in the secondary market.

 

Item 1B. Unresolved Staff Comments

 

None.

Item 2. Properties

Our principal executive office is located at 3651 Lindell Road, Suite D # 356, Las Vegas, Nevada 89103. The office is rented on a month to month basis from BSSI for about $70 per month, primarily to meet the state of Nevada’s requirements since Alkame is a virtual organization. This rent is prepaid on an annual basis. All aspects of production are simply drop shipped from our manufacturing facility in Hayden Idaho (source) to the recipients. We believe that our properties are adequate for our current needs, but growth potential may require a facility due to anticipated addition of personnel. We do not have any policies regarding investments in real estate, securities or other forms of property.

 

Item 3. Legal Proceedings

In April 2014, we were notified that a note holder disputes the balance of his note as recorded on the books of our company.  The discrepancy arises from a question regarding expenses that the holder claims were paid on behalf of our company and subsequent payments that we recorded as payments against the note.  We have no record of the expenses claimed to be due, and we are in negotiations to settle this matter.  We have accrued $28,000 to cover the potential expenses and adjustments to accrued interest if the claim is substantiated.  We believe it has properly accounted for all payments made to the individual and have provided documentation to him substantiating our position.

In May 2014, we received notice that a complaint was filed in District Court, Clark County, NV alleging that we and various unnamed defendants are liable to a Mr. Renard Wiggins with regard to commissions and equity purportedly owed Mr. Wiggins, for services allegedly rendered in raising capital on behalf of our company prior to the reverse merger between Pinacle Enterprises Inc. (now Alkame Holdings, Inc.) and Alkame Water, Inc. in September 2013. After initial review, we have filed for a dismissal of the case with the District Court, do not believe there is any validity to the claims of Mr. Wiggins, and intend to vigorously continue defending against these claims. At December 31, 2015, all but two claims had been dismissed, and we were in court mandated settlement talks to determine if the remaining counts could be dismissed or would require further litigation. On November 15, 2016, the Company entered into a stipulated settlement agreement to issue 200,000,000 common shares in full and final settlement of this matter and all legal complaints are withdrawn.  In June 2018, the Company issued 92,780,388 shares of the agreed upon settlement.

 

In April 2019, the Company entered into a settlement agreement with a vendor under which the Company has agreed to a payment schedule over a four-month period to liquidate the agree to balance of $45,000.  The Company has made the first payment, and so long as the remaining three payments are made in a timely manner, no further collection activity will occur.

 

In May 2019, the Company was made aware of a judgement totaling approximately $36,679 for past due invoices from a vendor.  The Company is contacting the attorney to make arrangements for the payment of the amounts due.

 

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

15


PART II

 

Item 5. Market for Registrant’s Common Equity and Related Stockholder Matters and Issuer Purchases of Equity Securities

 

Market Information

The following tables set forth the range of high and low prices for our common stock for the each of the periods indicated as reported by the OTC Markets. These quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily represent actual transactions. 

Year Ending December 31, 2016

 

High

 

Low

December 31, 2016

$0.0006

 

$0.0004

September 30, 2016

$0.0002

 

$0.0002

June 30, 2016

$0.0004

 

$0.0003

March 31, 2016

$0.0002

 

$0.0002

 

 Year Ending December 31, 2015

 

High

 

Low

December 31, 2015

$0.006

 

$0.0026

September 30, 2015

$0.0134

 

$0.0033

June 30, 2015

$0.0270

 

$0.0039

March 31, 2015

$0.0036

 

$0.0036

 

Our common stock is quoted under the symbol “ALKM” on the OTC Pink operated by OTC Markets Group, Inc.  Only a limited market exists for our securities. There is no assurance that a regular trading market will develop, or if developed, that it will be sustained. Therefore, a shareholder may be unable to resell his securities in our company.

 

Penny Stock

 

The SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a market price of less than $5.00, other than securities registered on certain national securities exchanges or quoted on the NASDAQ system, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or system. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock, to deliver a standardized risk disclosure document prepared by the SEC, that: (a) contains a description of the nature and level of risk in the market for penny stocks in both public offerings and secondary trading; (b) contains a description of the broker's or dealer's duties to the customer and of the rights and remedies available to the customer with respect to a violation of such duties or other requirements of the securities laws; (c) contains a brief, clear, narrative description of a dealer market, including bid and ask prices for penny stocks and the significance of the spread between the bid and ask price; (d) contains a toll-free telephone number for inquiries on disciplinary actions; (e) defines significant terms in the disclosure document or in the conduct of trading in penny stocks; and (f) contains such other information and is in such form, including language, type size and format, as the SEC shall require by rule or regulation.

 

The broker-dealer also must provide, prior to effecting any transaction in a penny stock, the customer with (a) bid and offer quotations for the penny stock; (b) the compensation of the broker-dealer and its salesperson in the transaction; (c) the number of shares to which such bid and ask prices apply, or other comparable information relating to the depth and liquidity of the market for such stock; and (d) a monthly account statement showing the market value of each penny stock held in the customer's account.

 

16

In addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from those rules, the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser's written acknowledgment of the receipt of a risk disclosure statement, a written agreement as to transactions involving penny stocks, and a signed and dated copy of a written suitability statement.

 

These disclosure requirements may have the effect of reducing the trading activity for our common stock. Therefore, stockholders may have difficulty selling our securities.

 

Holders of Our Common Stock

 

As of April 24, 2019, we had 5,500,000,000 shares of our common stock issued and outstanding, held by 32 shareholders of record, with numerous others in street name.

 

As of the date of this filing, the Company has issued all authorized common shares, and as such, can no longer issue common shares until such time as the Company has received approval from our shareholders, and have filed an increase in the authorized common shares with the State of Nevada.  

 

Dividends

 

There are no restrictions in our articles of incorporation or bylaws that prevent us from declaring dividends. The Nevada Revised Statutes, however, do prohibit us from declaring dividends where after giving effect to the distribution of the dividend:

 

1.       we would not be able to pay our debts as they become due in the usual course of business, or;

2.       our total assets would be less than the sum of our total liabilities plus the amount that would be needed to satisfy the rights of shareholders who have preferential rights superior to those receiving the distribution.

 

We have not declared any dividends and we do not plan to declare any dividends in the foreseeable future.

 

Securities Authorized for Issuance under Equity Compensation Plans

 

We do not have any equity compensation plans.

 

Recent Sales of Unregistered Securities

As of December 31, 2016, and 2015, there were 1,178,551,804 and 198,485,547 shares of common stock issued and outstanding, respectively.  

 

2016:

 

On February 9, 2016, the Company issued 4,500,000 common shares upon conversion of $7,020 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00156 per share.

 

On February 12, 2016, the Company issued 5,000,000 common shares upon conversion of $6,750 of convertible debt.  The shares were issued at a price of $0.00135 per share.

 

On February 16, 2016, the Company issued 5,454,545 common shares upon conversion of $7,500 of convertible debt.  The shares were issued at a price of $0.00138 per share.

 

On February 16, 2016, the Company issued 2,027,396 common shares upon conversion of $2,686 of convertible debt and accrued interest.  The shares were issued at a price of $0.00132 per share.

 

17


On February 17, 2016, the Company issued 10,226,900 common shares upon conversion of $8,949 of convertible debt.  The shares were issued at a price of $0.00088 per share.

 

On February 18, 2016, the Company issued 5,952,381 common shares upon conversion of $5,000 of convertible debt.  The shares were issued at a price of $0.00084 per share.

 

On February 22, 2016, the Company issued 18,552,879 common shares upon conversion of $10,000 of convertible debt.  The shares were issued at a price of $0.00054 per share.

 

On February 22, 2016, the Company issued 11,904,762 common shares upon conversion of $5,000 of convertible debt.  The shares were issued at a price of $0.00042 per share.

 

On February 22, 2016, the Company issued 9,904,429 common shares upon conversion of $4,160 of convertible debt.  The shares were issued at a price of $0.00042 per share.

 

On February 23, 2016, the Company issued 7,500,000 common shares upon conversion of $2,625 of convertible debt.  The shares were issued at a price of $0.00035 per share.

 

On February 24, 2016, the Company issued 21,636,364 common shares upon conversion of $5,950 of convertible debt.  The shares were issued at a price of $0.000275 per share.

 

On February 25, 2016, the Company issued 9,901,698 common shares upon conversion of $2,099 of convertible debt and accrued interest.  The shares were issued at a price of $0.00021 per share.

 

On February 26, 2016, the Company issued 10,226,909 common shares upon conversion of $818 of convertible debt.  The shares were issued at a price of $0.00008 per share.

 

On February 29, 2016, the Company issued 23,787,879 common shares upon conversion of $3,925 of convertible debt.  The shares were issued at a price of $0.00016 per share.

 

On February 29, 2016, the Company issued 7,500,000 common shares upon conversion of $1,125 of convertible debt.  The shares were issued at a price of $0.00015 per share.

 

On March 1, 2016, the Company issued 9,904,429 common shares upon conversion of $1,189 of convertible debt.  The shares were issued at a price of $0.00012 per share.

 

On March 2, 2016, the Company issued 23,852,814 common shares upon conversion of $2,755 of convertible debt.  The shares were issued at a price of $0.00012 per share.

 

On March 7, 2016, the Company issued 21,715,522 common shares upon conversion of $1,194 of convertible debt.  The shares were issued at a price of $0.00005 per share.

 

On March 7, 2016, the Company issued 2,102,660 common shares upon conversion of $116 of convertible debt.  The shares were issued at a price of $0.00005 per share.

 

On March 7, 2016, the Company issued 23,818,182 common shares upon conversion of $1,310 of convertible debt.  The shares were issued at a price of $0.000055 per share.

 

On March 8, 2016, the Company issued 9,725,791 common shares upon conversion of $195 of convertible debt.  The shares were issued at a price of $0.00002 per share.

 

On March 10, 2016, the Company issued 9,904,429 common shares upon conversion of $594 of convertible debt.  The shares were issued at a price of $0.00006 per share.

 

18


On March 10, 2016, the Company issued 23,818,182 common shares upon conversion of $1,310 of convertible debt.  The shares were issued at a price of $0.000055 per share.

 

On March 11, 2016, the Company issued 9,725,000 common shares upon conversion of $195 of convertible debt.  The shares were issued at a price of $0.00002 per share.

 

On March 15, 2016, the Company issued 9,904,429 common shares upon conversion of $594 of convertible debt.  The shares were issued at a price of $0.00006 per share

 

On March 16, 2016, the Company issued 23,818,182 common shares upon conversion of $1,310 of convertible debt.  The shares were issued at a price of $0.00005 per share.

 

On March 17, 2016, the Company issued 16,318,490 common shares upon conversion of $865 of convertible debt and accrued interest.  The shares were issued at a price of $0.00005 per share.

 

On March 18, 2016, the Company issued 9,904,429 common shares upon conversion of $594 of convertible debt.  The shares were issued at a price of $0.00006 per share

 

On March 23, 2016, the Company issued 20,500,000 common shares upon conversion of $12,300 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.0006 per share.

 

On March 23, 2016, the Company issued 9,904,429 common shares upon conversion of $594 of convertible debt.  The shares were issued at a price of $0.00024 per share.

 

On May 24, 2016, the Company issued 28,800,000 common shares upon conversion of $6,912 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00024 per share.

 

On June 16, 2016, the Company issued 30,250,000 common shares upon conversion of $3,630 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00012 per share.

 

On July 11, 2016, the Company issued 31,750,000 common shares upon conversion of $3,810 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00012 per share.

 

On July 25, 2016, the Company issued 33,300,000 common shares upon conversion of $3,996 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00012 per share.

 

On September 13, 2016, the Company issued 35,000,000 common shares upon conversion of $4,200 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00012 per share.

 

On October 13, 2016, the Company issued 36,500,000 common shares upon conversion of $4,380 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00012 per share.

 

On October 16, 2016, the Company issued 36,533,396 common shares upon conversion of $1,936 of convertible debt and accrued interest.  The shares were issued at a price of $0.000053 per share.

 

19

On October 25, 2016, the Company issued 38,500,000 common shares upon conversion of $4,620 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00012 per share.

 

On October 27, 2016, the Company issued 36,687,169 common shares upon conversion of $3,889 of convertible debt and accrued interest.  The shares were issued at a price of $0.00011 per share.

 

On October 28, 2016, the Company issued 42,300,000 common shares upon conversion of $7,614 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00018 per share.

 

On November 1, 2016, the Company issued 46,200,000 common shares upon conversion of $8,316 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00018 per share.

 

On November 1, 2016, the Company issued 19,827,273 common shares upon conversion of $2,181 of convertible debt.  The shares were issued at a price of $0.00011 per share.

 

On November 7, 2016, the Company issued 32,525,312 common shares upon conversion of $3,903 of convertible debt and accrued interest.  The shares were issued at a price of $0.00012 per share.

 

On November 14, 2016, the Company issued 48,500,000 common shares upon conversion of $29,100 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.0006 per share.

 

On November 18, 2016, the Company issued 50,900,000 common shares upon conversion of $12,216 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00024 per share.

 

On December 7, 2016, the Company issued 53,500,000 common shares upon conversion of $9,630 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00018 per share.

 

2015:

 

On January 12, 2015, the Company issued 3,600,000 common shares upon conversion of $69,336 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.01926 per share.

 

On February 4, 2015, the Company issued 3,000,000 common shares upon conversion of $54,000 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.018 per share.

 

On February 9, 2015, the Company issued 2,000,000 common shares upon conversion of $36,210 of convertible debt.  The shares were issued at a price of $0.01806 per share.

 

On February 17, 2015, the Company issued 1,428,571 common shares upon conversion of $25,000 of convertible debt.  The shares were issued at a price of $0.0175 per share.

 

On February 20, 2015, the Company issued 3,500,000 common shares upon conversion of $56,910 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.01626 per share.

 

20

On February 23, 2015, the Company issued 1,481,481 common shares upon conversion of $20,000 of convertible debt.  The shares were issued at a price of $0.0135 per share.

 

On February 24, 2015, the Company issued 1,750,000 common shares upon conversion of $17,850 of convertible debt.  The shares were issued at a price of $0.0102 per share.

 

On February 25, 2015, the Company issued 2,500,000 common shares upon conversion of $32,500 of convertible debt.  The shares were issued at a price of $0.013 per share.

 

On February 25, 2015, the Company issued 2,686,667 common shares upon conversion of $22,837 of convertible debt and accrued interest.  The shares were issued at a price of $0.0085 per share.

 

On February 26, 2015, the Company issued 1,518,333 common shares upon conversion of $18,220 of convertible debt and accrued interest.  The shares were issued at a price of $0.012 per share.

 

On March 5, 2015, the Company issued 1,800,000 common shares upon conversion of $13,500 of convertible debt.  The shares were issued at a price of $0.0075 per share.

 

On March 10, 2015, the Company issued 4,500,000 common shares upon conversion of $31,860 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00708 per share.

 

On March 12, 2015, the Company issued 3,424,658 common shares upon conversion of $25,000 of convertible debt.  The shares were issued at a price of $0.0073 per share.

 

On March 12, 2015, the Company issued 3,653,013 common shares upon conversion of $25,863 of convertible debt.  The shares were issued at a price of $0.00708 per share.

 

On March 12, 2015, the Company issued 4,955,500 common shares upon conversion of $33,797 of convertible debt and accrued interest.  The shares were issued at a price of $0.00682 per share.

 

On March 12, 2015, the Company issued 1,736,111 common shares upon conversion of $12,500 of convertible debt.  The shares were issued at a price of $0.0072 per share.

 

On March 16, 2015, the Company issued 1,000,000 common shares upon conversion of $6,700 of convertible debt and accrued interest.  The shares were issued at a price of $0.0067 per share.

 

On March 18, 2015, the Company issued 5,000,000 common shares upon conversion of $21,600 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00432 per share.

 

On March 26, 2015, the Company issued 5,697,909 common shares upon conversion of $19,886 of convertible debt and accrued interest.  The shares were issued at a price of $0.00349 per share.

 

On March 30, 2015, the Company issued 2,106,545 common shares upon conversion of $4,880 of convertible debt and accrued interest.  The shares were issued at a price of $0.00231 per share.

 

On March 31, 2015, the Company issued 6,600,000 common shares upon conversion of $15,048 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00228 per share.

 

On April 15, 2015, the Company issued 6,000,000 common shares upon conversion of $14,400 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.0024 per share.

 

21


On May 4, 2015, the Company issued 7,400,000 common shares upon conversion of $29,748 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00402 per share.

 

On June 2, 2015, the Company issued 5,118,865 common shares upon conversion of $30,713 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.006 per share.

 

On June 17, 2015, the Company issued 5,000,000 common shares upon conversion of $39,900 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00798 per share.

 

On August 5, 2015, the Company issued 8,000,000 common shares upon conversion of $26,880 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00336 per share.

 

On August 25, 2015, the Company issued 7,000,000 common shares upon conversion of $21,000 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.003 per share.

 

On September 28, 2015, the Company issued 5,482,288 common shares upon conversion of $10,855 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00198 per share.

 

On September 30, 2015 the Company recorded additional $24,718 as value of shares sold in payment of debt in excess of value in connection with the August and September 2015 settlements under the Section 3(a)10 of the Rules of the SEC.

 

On November 12, 2015, the Company issued 9,000,000 common shares upon conversion of $17,280 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00192 per share.

 

On December 9, 2015, the Company issued 2,000,000 Series D Convertible Preferred shares as compensation to its CEO and a consultant.  The shares were issued at a price of $0.003 per common share into which they are convertible.

 

On December 29, 2015, the Company issued 7,500,000 common shares upon conversion of $18,000 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.0024 per share.

 

On December 31, 2015 the Company recorded additional $21,056 as value of shares sold in payment of debt in excess of value in connection with the November and December 2015 settlements under the Section 3(a)10 of the Rules of the SEC.

 

 

  Item 6. Selected Financial Data

 

A smaller reporting company is not required to provide the information required by this Item.

 

 

 

 

22

 

 

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Forward-Looking Statements

 

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of complying with those safe-harbor provisions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Further information concerning our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.

 

Results of Operations for the Years Ended December 31, 2016 and 2015

 

We generated revenues of $185,270 for the year ended December 31, 2016, as compared with revenues of $898,381 for the year ended December 31, 2015. Revenue decreased significantly in 2016 as customers connected with the acquisition of Xtreme were dropped due to unprofitability.  

 

Our cost of sales was $232,723 for the year ended December 31, 2016, as compared with cost of sales of $858,477 for the year ended December 31, 2015. The current years decrease in cost of sales versus the prior year is due to the decrease in sales which covered much less of the manufacturing overhead.  We therefore had a gross loss of $47,453 for the year ended December 31, 2016, as compared with a gross profit of $39,904 for the year ended December 31, 2015.

 

We incurred operating expenses of $585,108 for the year ended December 31, 2016, as compared with $3,863,524 for the year ended December 31, 2015.  Our operating expenses decreased primarily as a result of impairment of our patents, goodwill, the customer list and trade names of $928,572, $658,187 and $343,750 respectively, and a decrease of $674,506 in administrative payroll, associated taxes and benefit costs from the acquisition of Xtreme, that occurred in 2015.  

 

We incurred other expenses of $1,289,304 for the year ended December 31, 2016, as compared with $683,286 for the year ended December 31, 2015.  We incurred interest expense of $460,930 for the year ended December 31, 2016, as compared with $182,242 for the year ended December 31, 2015. Default penalties during the year ended December 31, 2016 led to the majority of our increase in interest expense compared to the year ended December 31, 2015.  The decreases in expenses in 2016 was due to the reduction of overhead and expenses assumed in the acquisition of Xtreme at the beginning of 2015.  

 

During the years ended December 31, 2016 and 2015, we charged to other expenses $10,195 and $81,194 as amortization of deferred financing costs, respectively.  We recorded amortization of beneficial conversion feature of $44,509 and $713,118 for the years ended December 31, 2016 and 2015, respectively.  We also recognized derivative liability adjustments of $574,423 in expense and $289,994 of income for the years ended December 31, 2016 and 2015, respectively.  For the years ended December 31, 2016 and 2015, we also incurred losses on debt settlements of $199,247 and $25,630, respectively, and losses on debt conversion of $25,372 and $0, respectively.  

 

23


 

 

We incurred a net loss of $1,921,865 for the year ended December 31, 2016, as compared with a net loss of $4,506,906 for the year ended December 31, 2015. The decreased loss is predominantly due to the impairment of goodwill, patents, customer lists and trade names which combined totaled $1,930,509 as of December 31, 2015 versus $-0- for the period ended December 31, 2016.  

 

Liquidity and Capital Resources

 

As of December 31, 2016, we had current assets of $10,393 and total assets of $97,074. As of December 31, 2015, we had current assets of $113,142 and total assets of $255,143. The overall decrease in current assets is primarily a result of decreases in accounts receivable of $19,845, other receivables of $18,000, prepaid expenses of $5,000, inventory of $59,904.

 

We had current and total liabilities of $4,532,229 as of December 31, 2016. As of December 31, 2015, we had current liabilities of $4,452,468 and total liabilities of $4,506,527. The increase in liabilities is primarily a result of a net increase in notes payable of $107,500 offset by the conversion of $1,250,000 of notes and accrued interest into preferred shares, and increases in accounts payable and accrued expenses of $400,367, accrued interest net of conversions of $179,553, the amortization of debt discount of $44,510, loss on extinguishment of debt totaling $173,875 and $281,441 in default penalties, and the recording of a net increase to derivative liability of $574,423.

 

As such, we had a working capital deficit of $4,521,836 and $4,339,326 as of December 31, 2016 and 2015, respectively.

 

Cash Flow Analysis:

Net cash used in operating activities amounted to $80,496 for the year ended December 31, 2016 as compared to $497,304 for the year ended December 31, 2015. The $416,808 decrease in cash used was primarily attributable to a decrease in the net loss of $2,585,041, decreases in $59,904 in inventory and $18,000 in other receivables, increase of $579,920 in accounts payable and accrued expenses, $281,441 in accruals for liquidated damages, $574,423 in adjustments of the derivative instrument liability, loss on extinguishment of debt $173,875, amortization of debt discount of $44,510 offset by a decrease of $2,590 in customer deposits and an increase of $30,740 in accounts receivable.

 

Investing activities used $ 1,445 for the year ended December 31, 2016 as compared to $87,855 for the year ended December 31, 2015. In the year ended December 31, 2015, we made payments to Xtreme shareholders in connection with the acquisition of their shares, as well as purchasing additional equipment for operational needs, this was partially offset by cash acquired in the Xtreme deal.        

 

Financing activities provided $81,941 for the year ended December 31, 2016 as compared to $412,429 for the year ended December 31, 2015. Financing consisted of proceeds from notes payable of $107,500 offset by payments of notes payable of $12,956, and payments of loans from officers of $10,324.

 

EROP Settlement

 

On November 10, 2014, we entered into a Settlement Agreement and Stipulation (the “Settlement Agreement”) with EROP Capital, LLC, a Florida limited liability company (“EROP”), pursuant to which we agreed to issue common stock to EROP in exchange for the settlement of $796,451.55 (the “Settlement Amount”) of past-due obligations and accounts payable. EROP purchased the obligations and accounts payable from certain of our vendors.

 

On January 12, 2015, the Circuit Court of the Seventeenth Judicial Circuit for Broward County, Florida (the “Broward Court”), entered an order (the “EROP Order”) approving, among other things, the fairness of the terms and conditions of an exchange pursuant to Section 3(a)(10) of the Securities Act of 1933, as amended (the “Securities Act”), in accordance with a stipulation of settlement, pursuant to the Settlement Agreement between us and EROP, in the matter entitled EROP Capital, LLC v. Alkame Holdings, Inc . (the “EROP Action”). EROP commenced the EROP Action against us to recover an aggregate of $796,451.55 of past-due obligations and accounts payable (the “EROP Claim”), which EROP had purchased from certain of our vendors pursuant to the terms of separate receivable purchase

 

24

agreements between EROP and each of such vendors (the “EROP Assigned Accounts”). The EROP Assigned Accounts relate to certain contractual obligations and legal services provided to us. The EROP Order provides for the full and final settlement of the EROP Claim and the EROP Action. The Settlement Agreement became effective and binding upon us and EROP upon execution of the EROP Order by the Broward Court on January 12, 2015.

Pursuant to the terms of the Settlement Agreement approved by the EROP Order, on January 12, 2015, we agreed to issue to EROP shares (the “EROP Settlement Shares”) of our common stock, $0.001 par value (the “Common Stock”). The Settlement Agreement provides that the EROP Settlement Shares will be issued in one or more tranches, as necessary, sufficient to satisfy the EROP Settlement Amount through the issuance of freely trading securities issued pursuant to Section 3(a)(10) of the Securities Act. Pursuant to the Settlement Agreement, EROP may deliver a request to us which states the dollar amount (designated in U.S. Dollars) of Common Stock to be issued to EROP (the “EROP Share Request”). The parties agree that the total amount of Common Stock to be delivered by us to satisfy the EROP Share Request shall be issued at forty percent (40%) of the Common Stock over the Valuation Period (as defined in the Settlement Agreement). Additional tranche requests shall be made as requested by EROP until the EROP Settlement Amount is paid in full.

The Settlement Agreement provides that in no event shall the number of shares of Common Stock issued to EROP or its designee in connection with the Settlement Agreement, when aggregated with all other shares of Common Stock then beneficially owned by EROP and its affiliates (as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations thereunder), result in the beneficial ownership by EROP and its affiliates (as calculated pursuant to Section 13(d) of the Exchange Act and the rules and regulations thereunder) at any time of more than 9.99% of the Common Stock.

As of December 31, 2016, we had reserved up to 200,000,000 shares of Common Stock to provide for issuances upon full satisfaction of the Settlement Amount.  The balance to all creditors was satisfied in Q1-2017.  

 

Convertible Debt

 

We have issued a number of convertible debentures in the aggregate principal amounts of $82,530 and $362,233 during the years ended December 31, 2016 and 2015, respectively.  These debentures are more fully described in the footnotes to our audited consolidated financial statements and attached to our annual report as exhibits but are summarized below.

 

1. On January 7, 2015, we borrowed $28,000 under the terms of a convertible debenture. 

 

2. On January 22, 2015, we borrowed $75,000 under the terms of a convertible debenture. 

 

3. On February 9, 2015, we borrowed $108,000 under the terms of a convertible debenture. 

 

4. On February 10, 2015, we borrowed $22,000 under the terms of a convertible debenture. 

 

5. On February 24, 2015, we borrowed $35,000 under the terms of a convertible debenture. 

 

6. On February 25, 2015, we borrowed $33,333 under the terms of a convertible debenture. 

 

7. On March 13, 2015, we borrowed $52,500 under the terms of a convertible debenture. 

 

8. On October 7, 2015, we modified the terms of the convertible debenture and increased the principal amount of the debenture by $8,400, which resulted in the extinguishment of the convertible loan and the issuance of a note payable. 

 

9. On January 12, 2016, the company and a creditor, by mutual agreement converted $82,530 of accounts payable into a convertible note.    

  

25

 

Despite the steps we have taken to reduce our debt and secure additional financing, as described above, based upon our current financial condition, we do not have sufficient cash to operate our business at the current level for the next twelve months. We intend to fund operations through increased sales and debt and/or equity financing arrangements, which may be insufficient to fund expenditures or other cash requirements. We plan to seek additional financing in a private equity offering to secure funding for operations. There can be no assurance that we will be successful in raising additional funding. If we are not able to secure additional funding, the implementation of our business plan will be impaired. There can be no assurance that such additional financing will be available to us on acceptable terms or at all.

 

Going Concern

 

The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principle, which contemplate continuation of our company as a going concern.  However, we had limited revenues and continuing losses from operations as of December 31, 2016.  We currently have not completed our efforts to establish a stabilized source of revenues sufficient to cover operating costs over an extended period of time.  

 

Management anticipates that we will be dependent, for the near future, on additional investment capital to fund operating expenses. We intend to position our company so that we may be able to raise additional funds through the capital markets. In light of management’s efforts, there are no assurances that we will be successful in this or any of our endeavors or become financially viable and continue as a going concern.

Critical Accounting Policies

In December 2001, the SEC requested that all registrants list their most “critical accounting polices” in the Management Discussion and Analysis. The SEC indicated that a “critical accounting policy” is one which is both important to the portrayal of a company’s financial condition and results, and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. We do not believe that any accounting policies currently fit this definition.

Recently Issued Accounting Pronouncements

The FASB has issued ASU No. 2014-09, Revenue from Contracts with Customers. This ASU supersedes the revenue recognition requirements in Accounting Standards Codification 605 - Revenue Recognition and most industry-specific guidance throughout the Codification. The standard requires that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This ASU is effective on January 1, 2017 and should be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the ASU recognized at the date of initial application.

In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which provides further guidance on identifying performance obligations and improves the operability and understandability of licensing implementation guidance.

In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606) : Principal versus Agent Considerations (Reporting Revenue Gross versus Net) that clarifies how to apply revenue recognition guidance related to whether an entity is a principal or an agent. ASU 2016-08 clarifies that the analysis must focus on whether the entity has control of the goods or services before they are transferred to the customer and provides additional guidance about how to apply the control principle when services are provided and when goods or services are combined with other goods or services.

The effective date for ASU 2016-10 is the same as the effective date of ASU 2016-08 and ASU 2014-09 as amended by ASU 2015-14, for annual reporting periods beginning after December 15, 2017, including interim periods within those years.

Effective January 1, 2018, the Company will adopt the requirements of Topic 606 using the modified retrospective method. Upon adoption, the Company will recognize the cumulative effect of initially applying the new revenue

26

standard as an adjustment to the opening balance of retained earnings. Using the modified retrospective method of adoption, the comparative information for periods prior to 2018 will not be restated and instead will continue to be reported under the accounting standards in effect for those periods.

The Company anticipates that the adoption of the new standard will not result in a material difference between the recognition of revenue under Topic 606 and prior accounting standards. In addition, to meet the disaggregation disclosure requirements under Topic 606, the Company anticipates its disclosure of revenue disaggregation will be by major product group, geographic area and major sales channels.

Share-Based Compensation: Modification Accounting . In May 2017, the FASB issued an update to clarify when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award changes as a result of the change in terms or conditions. This authoritative guidance will be applied prospectively to awards modified following adoption and will be effective for Alkame in the first quarter of fiscal 2019 with early adoption permitted. The impact of the adoption of this guidance will depend on whether the Company has any share-based payment awards or makes any future modifications of share-based payment awards.

Retirement Benefits. In March 2017 , the FASB issued authoritative guidance which requires companies to present the service cost component of net benefit cost in the same line items in which they report compensation cost. The other components of net benefit cost are required to be presented in the income statement separately from the service cost component and outside a subtotal of income from operations, if one is presented. The authoritative guidance will be effective for Alkame in the first quarter of fiscal 2019 on a retrospective basis, with early adoption permitted. The adoption of this guidance is only expected to result in reclassification of other components of net benefit costs outside of income from operations and is not expected to have a significant impact on Alkame’s consolidated financial statements as the Company does not have such a plan at this time.

Business Combinations. In January 2017 , the FASB issued authoritative guidance that clarifies the definition of a business to help companies evaluate whether acquisition or disposal transactions should be accounted for as asset groups or as businesses. The authoritative guidance will be effective for Alkame in the first quarter of fiscal 2019 on a prospective basis, with early adoption permitted. The impact of the adoption depends on the facts and circumstances of future acquisition or disposal transactions.

Income Taxes: Intra-Entity Asset Transfers. In October 2016, the FASB issued authoritative guidance that requires entities to recognize at the transaction date the income tax consequences of intercompany asset transfers other than inventory. The authoritative guidance will be effective for Alkame in the first quarter of fiscal 2019, with early adoption permitted. Alkame is currently evaluating the effect of this new guidance on Alkame’s consolidated financial statements.

Classification of Certain Cash Receipts and Cash Payments . In August 2016, the FASB issued authoritative guidance which addresses classification of certain cash receipts and cash payments related to the statement of cash flows. The authoritative guidance will be effective for Alkame in the first quarter of fiscal 2019. The adoption of this guidance is not expected to have a significant impact on Alkame’s consolidated financial statements.

Share-Based Compensation. In March 2016 , the FASB issued authoritative guidance that simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, forfeitures, classification of awards as either equity or liabilities, and classification on the statement of cash flows. Alkame plans to adopt the authoritative guidance effective in the first quarter of fiscal 2018. Upon adoption, Alkame will elect to continue to estimate forfeitures expected to occur to determine the amount of compensation cost to be recognized in each period. The new standard will result in the recognition of excess tax benefits in provision for income taxes rather than paid-in capital prospectively, which is expected to increase volatility in Alkame’s results of operations. Alkame will elect to apply the presentation requirements for cash flows related to excess tax benefits retrospectively. The presentation requirements for cash flows related to employee taxes paid for withheld shares will be presented as a financing activity retrospectively, as required. Alkame expects cash flow from operations to increase, with a corresponding decrease in cash flow from financing activity as a result of the changes in the cash flow presentation.

 

27


Leases. In February 2016 , the FASB issued authoritative guidance for lease accounting, which requires lessees to recognize lease assets and liabilities on the balance sheet for certain lease arrangements that are classified as operating leases under the previous standard, and to provide for enhanced disclosures. The authoritative guidance will be effective for Alkame in the first quarter of fiscal 2020 and should see Alkame using a modified retrospective approach. Early adoption is permitted. Alkame is currently evaluating the effect of this new guidance on Alkame’s consolidated financial statements.

Financial Instruments: Classification and Measurement . In January 2016, the FASB issued authoritative guidance that requires equity investments that do not result in consolidation, and are not accounted for under the equity method, to be measured at fair value, and requires recognition of any changes in fair value in net income unless the investments qualify for a new practicability exception. For financial liabilities measured at fair value, the change in fair value caused by a change in instrument-specific credit risk will be required to be presented separately in other comprehensive income. The authoritative guidance will be effective for
Alkame in the first quarter of fiscal 2019. Early adoption is permitted only for the provisions related to the recognition of changes in fair value of financial liabilities caused by instrument-specific credit risk. Alkame is currently evaluating the effect of this new guidance on Alkame’s consolidated financial statements.

Inventory: In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory (Topic 330). ASU 2015-11 simplifies the accounting for the valuation of all inventory not accounted for using the last-in, first-out (“LIFO”) method by prescribing that inventory be valued at the lower of cost and net realizable value. ASU 2015-11 is effective for financial statements issued for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016 on a prospective basis. Alkame is currently evaluating the effect of this new guidance on Alkame’s consolidated financial statements.

The Company has implemented all new accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

 

 

Off Balance Sheet Arrangements

 

As of December 31, 2016, there were no off-balance sheet arrangements.

 

Inflation

 

The effect of inflation on the Company's revenue and operating results was not significant.

 

 

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

 

A smaller reporting company is not required to provide the information required by this Item.

 

28

 

Item 8. Financial Statements and Supplementary Data

 

 

 

 

 

 

Index to Consolidated Financial Statements Required by Article 8 of Regulation S-X:

 

 

 

 

Report of Independent Registered Public Accounting Firm

F-1

Consolidated Balance Sheets as of December 31, 2016 and 2015

F-2

Consolidated Statements of Operations for the years ended December 31, 2016 and 2015

F-3

Consolidated Statements of Stockholders’ Deficit for the two years in the period ended December 31, 2016

F-4

Consolidated Statements of Cash Flows for the years ended December 31, 2016 and 2015

F-5

Notes to the Consolidated Financial Statements

F-6

 

 

 

 

29

Report of Independent Registered Public Accounting Firm

 

 

 

To the Board of Directors and Shareholders of

Alkame Holdings, Inc.

 

We have audited the accompanying consolidated balance sheets of Alkame Holdings, Inc. (the “Company”) as of December 31, 2016 and 2015, and the related consolidated statements of operations, stockholders’ deficit and cash flows for the two years in the period ended December 31, 2016. These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.

 

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Company’s internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

 

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Alkame Holdings, Inc. at December 31, 2016 and 2015, and the results of its operations and its cash flows for the two years in the period ended December 31, 2016, in conformity with accounting principles generally accepted in the United States of America.

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has sustained net losses from operations and stockholder’s deficit. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.  Management’s plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

/s/ RBSM LLP

 

May 24, 2019

New York, New York

 

 

 

 

 

 

 

 

 

 

 

F-1


ALKAME HOLDINGS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

 

 

 

 

 

December 31,

 

December 31,

 

2016

 

2015

ASSETS

 

 

 

                 Current assets:

 

 

 

                     Accounts receivable (net of reserve for bad debts of $12,499 and $161,000, respectively)

$ 8,393   

 

$ 28,238   

                     Other receivables

 

 

18,000   

                     Prepaid expenses

2,000   

 

7,000   

                     Inventory

 

 

59,904   

                 Total current assets

10,393   

 

113,142   

 

 

 

 

                 Fixed and intangible assets:

 

 

 

                     Furniture and fixtures, net

824   

 

 

                     Manufacturing equipment, net

79,016   

 

122,829   

                     Software, net

6,620   

 

11,997   

                     Intangible assets, net

 

 

1,662   

                 Fixed and intangible assets, net

86,459   

 

136,488   

 

 

 

 

                 Other assets:

 

 

 

                     Deferred finance costs

222   

 

5,513   

                  Total other assets

222   

 

5,513   

 

 

 

 

                  Total assets

$ 97,074   

 

$ 255,143   

 

 

 

 

LIABILITIES AND STOCKHOLDERS DEFICIT

 

 

 

                 Current liabilities:

 

 

 

                     Cash overdraft

$ 169   

 

$ 2,448   

                     Accounts payable and accrued expenses

796,670   

 

727,290   

                     Accrued interest

255,232   

 

272,391   

                     Accrued compensation – related parties

727,270   

 

513,480   

                     Customer deposits

14,580   

 

17,170   

                     Legal obligations

120,000   

 

120,000   

                     Accrued contingencies

134,000   

 

 

                     Loans from officer

16,132   

 

26,456   

                     Notes payable (net of debt discount of $-0- and $35,095, respectively)

295,330   

 

991,119   

                     Note due Xtreme Shareholders

105,500   

 

183,000   

                     Convertible debt (net of debt discount of $109,774 and $27,411, respectively)

634,696   

 

552,479   

                     Derivative instrument liability

1,432,650   

 

1,046,635   

                 Total current liabilities

4,532,229   

 

4,452,468   

 

 

 

 

                 Long-term liabilities:

 

 

 

                      Notes payable - long term

 

 

24,573   

                      Convertible debt - long term (net of debt discount of $-0- and $25,847, respectively)

 

 

29,486   

                 Total long-term liabilities

 

 

54,059   

 

 

 

 

                 Total liabilities

4,532,229   

 

4,506,527   

 

 

 

 

                 Commitments and contingencies

 

 

 

 

 

 

 

                  Stockholders’ deficit

 

 

 

 

                    Preferred stock - $0.001 par value, authorized - 100,000,000 shares;

 

 

 

              Series A Convertible Preferred stock - $0.001 par value, 12,000,000 shares

              designated; shares issued and outstanding - 12,000,000 and 12,000,000

              shares respectively

12,000   

 

12,000   

              Series B Convertible Preferred stock - $0.001 par value, 70,000,000 shares

             designated; shares issued and outstanding - 65,398,334 and 65,398,334

             shares, respectively

65,398   

 

65,398   

              Series C Convertible Preferred stock - $0.001 par value, 1,250,000 shares 

             designated; shares issued and outstanding - 0 and 0 shares, respectively

 

 

 

              Series D Convertible Preferred stock - $0.001 par value, 4,000,000 shares

              designated; shares issued and outstanding - 2,000,000 and 2,000,000 shares,

              respectively

2,000   

 

2,000   

              Series E Convertible Preferred stock - $0.001 par value, 1,250,000 shares

             designated; shares issued and outstanding - 0 and 0 shares, respectively

 

 

 

             Common stock - $0.001 par value, authorized 5,500,000,000 and 900,000,000 

             shares respectively; issued and outstanding 1,178,551,804 and 198,485,547

             shares, respectively

1,178,552   

 

198,486   

             Common stock to be issued

13,500   

 

13,500   

             Series C Convertible Preferred Stock to be issued

1,425,000   

 

1,425,000   

             Series E Convertible Preferred Stock to be issued

1,250,000   

 

                   -

             Additional paid-in capital

6,518,516   

 

7,010,488   

             Accumulated deficit

(14,900,121)  

 

(12,978,256)  

                   Total stockholders' deficit

(4,435,155)  

 

(4,251,384)  

 

 

 

 

                   Total liabilities and stockholders' deficit

$ 97,074   

 

$ 255,143   

 

 

 

 

See accompanying notes to the consolidated financial statements

F-2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


ALKAME HOLDINGS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

 

 

 

 

 

For the years ended

 

December 31, 2016

 

December 31, 2015

 

 

 

 

  Revenues

$                 185,270

 

$               898,381

 

 

 

 

  Cost of goods sold

                   232,723

 

                 858,477

 

 

 

 

  Gross (loss) profit

                   (47,453)

 

                   39,904

 

 

 

 

  Operating expenses:

 

 

 

     Selling expenses

                   152,315

 

                 585,352

     General and administrative

                   425,133

 

              1,211,139

     Depreciation and amortization

                       7,660

 

                 136,523

     Impairment of goodwill

                             -   

 

                 658,187

     Impairment of patents

                             -   

 

                 928,572

     Impairment customer list & trade names

                             -   

 

                 343,750

   Total operating expenses

                   585,108

 

              3,863,524

 

 

 

 

   Loss from operations

                  (632,561)

 

             (3,823,620)

 

 

 

 

   Other Income (Expense):

 

 

 

     Amortization of deferred financing costs

                     (10,195)

 

                  (81,194)

     Interest expense

                   (460,930)

 

                 (182,242)

     Amortization of beneficial conversion feature

                     (44,509)

 

                 (713,118)

    (Loss) gain on change in fair value of derivative liability

                   (574,423)

 

                    289,994

    Loss on conversion of debt

                     (25,372)

 

                               -

    Gain on extinguishment of debt

                                 -

 

                     28,904

    Loss on settlement of debt

                   (173,875)

 

                  (25,630)

  Total other expenses

                (1,289,304)

 

                (683,286)

 

 

 

 

  Net loss applicable to common stock holders

$               (1,921,865)

 

$           (4,506,906)

 

 

 

 

  Per share data

 

 

 

    Net Loss per share - basic and diluted

$                      (0.00)

 

$                    (0.03)

 

 

 

 

  Weighted average number of

 

 

 

   shares outstanding- basic and diluted

            655,439,620

 

          149,785,191

 

 

 

 

See accompanying notes to the consolidated financial statements

F-3


 

ALKAME HOLDINGS, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Series A Convertible Preferred Stock

 

Preferred B Stock

 

Preferred D Stock

 

Common Stock

 

 

 

Additional

 

 

 

Total

 

($0.001 par value)

 

($0.001 par value)

 

($0.001 par value)

 

($0.001 par value)

 

Stock

 

Paid-In

 

Accumulated

 

Stockholders'

 

Shares

 

Amount

 

Shares

 

Amount

 

Shares

 

Amount

 

Shares

 

Amount

 

To be issued

 

Capital

 

Deficit

 

Equity (Deficit)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

   Balance, January 1, 2015

12,000,000  

 

$ 12,000  

 

65,398,334  

 

$ 65,398  

 

-  

 

$ -  

 

74,045,606

 

$ 74,046  

 

$ 13,500  

 

$ 6,259,050   

 

$ (8,471,350)  

 

$ (2,047,356)  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

   Issuance of stock for:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  Conversion of debentures and accrued interest

 

 

 

 

 

 

 

 

 

 

 

 

37,738,788

 

37,739  

 

 

 

276,914   

 

 

 

314,653   

  Settlement of accounts payable

 

 

 

 

 

 

 

 

 

 

 

 

86,701,153

 

86,701  

 

 

 

416,524   

 

 

 

503,225   

   Issuance series D Preferred Stock for employment and consulting services

 

 

 

 

 

 

 

 

2,000,000  

 

2,000  

 

 

 

 

 

 

 

58,000   

 

 

 

60,000   

   Series C Preferred Stock to be issued for the acquistion of Xtreme

 

 

-  

 

 

 

-  

 

 

 

-  

 

-

 

-  

 

1,425,000  

 

 

 

 

 

1,425,000   

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

   Net loss

 

 

-  

 

 

 

-  

 

 

 

-  

 

-

 

-  

 

-  

 

 

 

(4,506,906)  

 

(4,506,906)  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

   Balance, December 31, 2015

12,000,000  

 

12,000  

 

65,398,334  

 

65,398  

 

2,000,000  

 

2,000  

 

198,485,547

 

198,486  

 

1,438,500  

 

7,010,488   

 

(12,978,256)  

 

(4,251,384)  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

   Issuance of stock for:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  Conversion of debentures and accrued interest

 

 

-  

 

 

 

-  

 

 

 

-  

 

479,566,257

 

479,566  

 

 

 

(191,746)  

 

 

 

278,820   

  Settlement of accounts payable

 

 

-  

 

 

 

-  

 

 

 

-  

 

500,500,000

 

500,500  

 

 

 

(382,756)  

 

 

 

117,744   

   Series E Convertible Preferred stock to be issued to settle notes payable and accrued interest

 

 

-  

 

 

 

-  

 

 

 

-  

 

 

 

-  

 

1,250,000  

 

 

 

 

 

1,250,000   

   Beneficial conversion feature on convertible debenture

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

82,530  

 

 

 

           82,530   

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

   Net loss

 

 

-  

 

 

 

-  

 

 

 

-  

 

-

 

-  

 

 

 

 

 

(1,921,865)  

 

(1,921,865)  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

   Balance, December 31, 2016

12,000,000  

 

$ 12,000  

 

65,398,334  

 

$ 65,398  

 

2,000,000  

 

$ 2,000  

 

1,178,551,804

 

$ 1,178,552  

 

$ 2,688,500  

 

$ 6,518,516   

 

$ (14,900,121)  

 

$ (4,435,155)  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

See accompanying notes to the consolidated financial statements

F-4


ALKAME HOLDINGS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

 

 

 

 

For the years Ended

 

December 31, 2016

 

December 31, 2015

              Cash flows from operating activities:

 

 

 

          Net loss

$             (1,921,865)

 

$           (4,506,906)

           Adjustments to reconcile net loss to net cash used in operating activities:            

 

 

 

             Bad debts

   50,585 

 

              138,000 

             Depreciation and amortization

  51,474   

 

              160,186

             Series D Convertible Preferred shares issued for services

 

 

                60,000 

             Impairment of intangible assets

 

 

           1,930,509

             Amortization debt discount

                44,510

 

                 16,905 

             Amortization of beneficial conversion feature

           - 

 

 713,118

             Change in fair value of derivative liability

             574,423

 

             (289,994)    

             Liquidated damages and default penalties

             281,441 

 

                         -

            Amortization of prepaid expenses

        5,000

 

             253,000

            Amortization of deferred financing costs

      10,195

 

       81,194 

            Loss (gain) on extinguishment of debt

    173,875 

 

      (28,904)

            Loss on conversion of debt

      25,372

 

                -

            Loss on disposition of terminated joint ventures

               -

 

        25,630

              Changes in operating asset and liability account balances:

 

 

 

            Accounts receivable

     (30,740)

 

      (24,430)

            Other receivable

       18,000

 

      (17,654)

            Inventory

       59,904

 

       85,519

            Customer deposit

       (2,590)

 

            -

            Accrued interest

     179,553

 160,167

            Accounts payable and accrued expenses

              400,367

 

              750,356

          Total adjustments

           1,841,369 

 

           4,009,602

 

 

 

 

              Net cash used in operating activities

              (80,496) 

 

            (497,304)

 

 

 

 

              Cash flows from investing activities

 

 

 

     Payment of purchase consideration to Xtreme Technologies, Inc.

               -

 

     (45,100)

     Cash acquired from Xtreme Technologies, Inc.

               -

 

      13,287

     Funds spent on potential joint venture

               -

 

     (12,130)

     Purchase of equipment

       (1,445)

 

     (43,912)

               Net cash used in investing activities

                (1,445)

 

              (87,855)

 

 

 

 

              Cash flows from financing activities:

 

 

 

     Cash overdraft

                (2,279)

 

                 2,448

     (Repayment) proceeds from officer loans

              (10,324)

 

               22,967

     Payments of convertible notes

                        -

 

              (22,783)

     Proceeds from convertible notes payable

                        -

 

              353,833

     Payments of notes payable

              (12,956)

 

            (109,296)

     Proceeds from notes payable

             107,500

 

              165,260

              Net cash provided by financing activities

               81,941      

                  

              412,429     

 

 

           

 

              Net decrease in cash

                        -

 

            (172,730)

  

 

 

 

              Cash at beginning of year

                        -

 

              172,730

 

 

 

 

              Cash at end of year

$                          -   

 

$                         -

 

 

 

 

              Supplemental Schedule of Cash Flow Information:

 

 

 

                   Cash paid for interest

$                  3,724

 

$                 20,788

                   Cash paid for income taxes

$                         -

 

$                          -

 

 

 

 

              Supplemental Schedules of Noncash Investing and Financing Activities:

 

 

 

               Conversion of notes payable and accrued interest into shares

$                91,310

 

$               314,653

               Conversion of convertible loans and accrued interest to notes payable

$                         -

 

$                 36,400

               Common stock issued to settle accounts payable

$              117,744

 

$               503,225

               Payment made by EROP to noteholders on Company's behalf

$                77,500

 

$               342,000

               Assets taken over and liabilities assumed from Xtreme Technologies, 

               Inc. acquistion

$                        -

 

$             2,050,000

              Convertible note payable issued to settle accounts payable

$                82,500

 

$                           -

              Beneficial conversion feature on convertible debt

$                82,500

 

$                353,832

              Series E Convertible Preferred Stock to be Issued to settle notes payable and    

              accrued interes

$           1,250 000 

 

$                          - 

 

 

 

 

See accompanying notes to the consolidated financial statements

F-5


Alkame Holdings, Inc. and Subsidiaries

Notes to the Consolidated Financial Statements

  For the years ended December 31, 2016 and 2015

 

 

1. Organization and Nature of Operations  

 

Alkame Holdings, Inc. (fka Pinacle Enterprise Inc.) (the "Company", “we”, “us” or “our”) was incorporated under the laws of the State of Nevada on April 19, 2010.  The Company is in the business of distributing bottled alkaline, antioxidant and oxygenated water.

On June 24, 2013, the Company entered into a share exchange agreement with Alkame Water, Inc. (“Alkame”) and the shareholders of all of the issued and outstanding shares of Alkame. On June 25, 2013, the Company acquired 100% of the members’ shares of Alkame, a Company incorporated in the state of Nevada on March 1, 2012, in exchange for 150,000,000 common shares, comprised of 116,666,667 common shares privately transacted from the President of the Company and the issuance of 33,333,333 common shares to shareholders of Alkame.  Effectively, Alkame held 71% of the issued and outstanding common shares of the Company and the transaction has been accounted for as a reverse merger, where Alkame is deemed to be the acquirer and or the surviving entity for accounting purposes.

As part of the acquisition transaction, all assets and liabilities of Alkame Holdings, Inc. at the date of acquisition were assumed by the former management.

The transaction is accounted for using the purchase method of accounting. As a result of the recapitalization and change in control, Alkame is the acquiring entity in accordance with ASC 805, Business Combinations. Accordingly, the historical financial statements are those of Alkame, the accounting acquirer, immediately following the consummation of the reverse merger.

As a result of the exchange transaction in 2013, our board of directors decided to change our fiscal yearend from January 31 to December 31.

On April 21, 2014, we entered into a Stock Purchase Definitive Agreement (the “Agreement”) with Xtreme Technologies, Inc., an Idaho corporation (“Xtreme”). Pursuant to the terms of the Agreement, we agreed to acquire all of the issued and outstanding capital stock of Xtreme in exchange for certain consideration as set forth in the Agreement.

On January 16, 2015, the parties to the Agreement entered into an amendment (the “Amendment”) that changed, among other things, the Closing Date of the transaction.

On April 15, 2015, the parties to the Agreement entered into a second amendment (the “Second Amendment”) that changed, among other things, the 120-day time period to pay monetary consideration under the Agreement to 240 days after the Closing Date of the transaction.  

In February 2017, the final cash payments under the Agreement were completed.

 

2. Going Concern  

 

The accompanying consolidated financial statements have been prepared using accounting principles generally accepted in the United States of America applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business.  The Company has an accumulated deficit of $14,900,121 and has incurred a net loss of $1,921,865 for the year ended December 31, 2016. The Company's ability to continue as a going concern is dependent upon its ability to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due, and to generate profitable operations in the future. Management plans to continue to provide for its capital requirements by seeking long term financing which may be in the form of additional equity securities and debt. The outcome of these matters cannot be predicted at this time and there are no assurances that if achieved, the Company will have sufficient funds to execute its business plan or generate positive operating results.

 

F-6


These matters, among others, raise substantial doubt about the ability of the Company to continue as a going concern. These consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern.

 

3. Summary of Significant Accounting Policies  

 

a)   Basis of Presentation

The consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) and are expressed in U.S. dollars. All inter-company accounts and transactions have been eliminated. The Company’s fiscal year end is December 31.

 

b)  Principles of Consolidation

The consolidated financial statements include the accounts of Alkame Holdings, Inc. (parent), Alkame Water, Inc., and Xtreme Technologies, Inc. our wholly owned subsidiaries which have common ownership and management.  All intercompany balances and transactions have been eliminated.

 

c)  Use of Estimates

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Significant estimates included are assumptions about collection of accounts receivable, useful life of fixed and intangible assets, impairment analysis of goodwill and intangible assets, estimates used in the fair value calculation of stock-based compensation, beneficial conversion feature and derivative liability on convertible notes and warrants using Black-Scholes Model.

 

d)   Cash and Cash Equivalents

For purposes of the statement of cash flows, cash includes demand deposits, saving accounts and money market accounts. The Company considers all highly liquid instruments with maturities of three months or less when purchased to be cash equivalents.

 

e)   Financial Instruments

Pursuant to ASC 820, Fair Value Measurements and Disclosures, an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:

Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

 

F-7

Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

The Company’s financial instruments consist principally of cash, accounts payable and accrued liabilities and amounts due to related parties. Pursuant to ASC 820, the fair value of our cash is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. We believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.

f)   Basic and Diluted Net Loss per Share

The Company computes net loss per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement. Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive.

As of

 

December 31,

 

2016

 

2015

Series A Convertible Preferred Stock

600,000,000  

 

600,000,000  

Series B Convertible Preferred Stock

65,398,334  

 

65,398,334  

Series D Convertible Preferred Stock

20,000,000  

 

20,000,000  

3(a)10 Shares Issuances

190,849,500  

 

691,349,500  

Convertible notes payable

4,037,818,308  

 

392,190,145  

Warrants

1,587,302  

 

1,587,302  

 

g)   Income Taxes

Potential benefits of income tax losses are not recognized in the accounts until realization is more likely than not. The Company has adopted ASC 740 “Accounting for Income Taxes” as of its inception. Pursuant to ASC 740, the Company is required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in this financial statement because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years.

h)   Revenue Recognition

The Company recognizes revenue in accordance with ASC-605, “Revenue Recognition,” which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or title has passed; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management's judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts.

Revenues are recognized upon shipment, provided that a signed purchase order has been received, the price is fixed, title has transferred, collection of resulting receivables is reasonably assured, and there are no remaining significant obligations. Reserves for sales returns and allowances, including allowances for so called “ship and debit” transactions, are recorded at the time of shipment, based on historical levels of returns and discounts, current economic trends and changes in customer demand. Certain internet generated transactions that are prepaid at time of order, are recognized at the time the merchandise ships from the warehouse to the customer.  

 

F-8


Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company will defer any revenue for which the product has not been delivered or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered or no refund will be required.

i)   Accounts receivable and concentration of credit risk

Because the Company currently uses distributors as their main source of product sales and placement, there is an inherent risk that the distributor could experience difficulty in their payments for accounts they ship to.  The result may be that while collecting from the stores and chains they supply; the distributors do not process through the payments to the Company.  Although in the past the Company did see significant credit risk associated with the trade receivables, repayment is dependent upon the financial stability of the various distributors and customers to which shipment takes place.  As a result, the Company is looking more closely at the credit worthiness of its customers and how large a footprint and customer base various distributors have and is attempting to limit how much of our business is conducted through any one customer or distributor.  Our concentration risk is reevaluated on a quarterly basis.

 

j)   Allowance for doubtful accounts

The allowance for doubtful accounts is based on the Company’s assessment of the collectability of customer accounts and the aging of the accounts receivable.  The Company regularly reviews the adequacy of the Company’s allowance for doubtful accounts through identification of specific receivables where it is expected that payments will not be received.  The Company also establishes an unallocated reserve that is applied to all amounts that are not specifically identified.  In determining specific receivables where collections may not have been received, the Company reviews past due receivables and gives consideration to prior collection history and changes in the customer’s overall business condition.  The allowance for doubtful accounts reflects the Company’s best estimate as of the reporting dates.

At December 31, 2016 and 2015, the Company had an allowance for bad debts in the amount of $12,499 and $161,000 respectively.

 

k)  Related Party Transactions

Parties are considered to be related to the Company if the parties that, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. The Company discloses all related party transactions. All transactions are recorded at fair value of the goods or services exchanged.

 

l)  Recent Accounting Pronouncements

The FASB has issued ASU No. 2014-09, Revenue from Contracts with Customers. This ASU supersedes the revenue recognition requirements in Accounting Standards Codification 605 - Revenue Recognition and most industry-specific guidance throughout the Codification. The standard requires that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This ASU is effective on January 1, 2017 and should be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the ASU recognized at the date of initial application.

In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which provides further guidance on identifying performance obligations and improves the operability and understandability of licensing implementation guidance.

 

F-9

In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606) : Principal versus Agent Considerations (Reporting Revenue Gross versus Net) that clarifies how to apply revenue recognition guidance related to whether an entity is a principal or an agent. ASU 2016-08 clarifies that the analysis must focus on whether the entity has control of the goods or services before they are transferred to the customer and provides additional guidance about how to apply the control principle when services are provided and when goods or services are combined with other goods or services.

The effective date for ASU 2016-10 is the same as the effective date of ASU 2016-08 and ASU 2014-09 as amended by ASU 2015-14, for annual reporting periods beginning after December 15, 2017, including interim periods within those years.

Effective January 1, 2018, the Company will adopt the requirements of Topic 606 using the modified retrospective method. Upon adoption, the Company will recognize the cumulative effect of initially applying the new revenue standard as an adjustment to the opening balance of retained earnings. Using the modified retrospective method of adoption, the comparative information for periods prior to 2018 will not be restated and instead will continue to be reported under the accounting standards in effect for those periods.

The Company anticipates that the adoption of the new standard will not result in a material difference between the recognition of revenue under Topic 606 and prior accounting standards. In addition, to meet the disaggregation disclosure requirements under Topic 606, the Company anticipates its disclosure of revenue disaggregation will be by major product group, geographic area and major sales channels.

Share-Based Compensation: Modification Accounting . In May 2017, the FASB issued an update to clarify when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award changes as a result of the change in terms or conditions. This authoritative guidance will be applied prospectively to awards modified following adoption and will be effective for Alkame in the first quarter of fiscal 2019 with early adoption permitted. The impact of the adoption of this guidance will depend on whether the Company has any share-based payment awards or makes any future modifications of share-based payment awards.

Retirement Benefits. In March 2017 , the FASB issued authoritative guidance which requires companies to present the service cost component of net benefit cost in the same line items in which they report compensation cost. The other components of net benefit cost are required to be presented in the income statement separately from the service cost component and outside a subtotal of income from operations, if one is presented. The authoritative guidance will be effective for Alkame in the first quarter of fiscal 2019 on a retrospective basis, with early adoption permitted. The adoption of this guidance is only expected to result in reclassification of other components of net benefit costs outside of income from operations and is not expected to have a significant impact on Alkame’s consolidated financial statements as the Company does not have such a plan at this time.

Business Combinations. In January 2017 , the FASB issued authoritative guidance that clarifies the definition of a business to help companies evaluate whether acquisition or disposal transactions should be accounted for as asset groups or as businesses. The authoritative guidance will be effective for Alkame in the first quarter of fiscal 2019 on a prospective basis, with early adoption permitted. The impact of the adoption depends on the facts and circumstances of future acquisition or disposal transactions.

Income Taxes: Intra-Entity Asset Transfers. In October 2016, the FASB issued authoritative guidance that requires entities to recognize at the transaction date the income tax consequences of intercompany asset transfers other than inventory. The authoritative guidance will be effective for Alkame in the first quarter of fiscal 2019, with early adoption permitted. Alkame is currently evaluating the effect of this new guidance on Alkame’s consolidated financial statements.

Classification of Certain Cash Receipts and Cash Payments . In August 2016, the FASB issued authoritative guidance which addresses classification of certain cash receipts and cash payments related to the statement of cash flows. The authoritative guidance will be effective for Alkame in the first quarter of fiscal 2019. The adoption of this guidance is not expected to have a significant impact on Alkame’s consolidated financial statements.

 

F-10


Share-Based Compensation. In March 2016 , the FASB issued authoritative guidance that simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, forfeitures, classification of awards as either equity or liabilities, and classification on the statement of cash flows. Alkame plans to adopt the authoritative guidance effective in the first quarter of fiscal 2018. Upon adoption, Alkame will elect to continue to estimate forfeitures expected to occur to determine the amount of compensation cost to be recognized in each period. The new standard will result in the recognition of excess tax benefits in provision for income taxes rather than paid-in capital prospectively, which is expected to increase volatility in Alkame’s results of operations. Alkame will elect to apply the presentation requirements for cash flows related to excess tax benefits retrospectively. The presentation requirements for cash flows related to employee taxes paid for withheld shares will be presented as a financing activity retrospectively, as required. Alkame expects cash flow from operations to increase, with a corresponding decrease in cash flow from financing activity as a result of the changes in the cash flow presentation.

Leases. In February 2016 , the FASB issued authoritative guidance for lease accounting, which requires lessees to recognize lease assets and liabilities on the balance sheet for certain lease arrangements that are classified as operating leases under the previous standard, and to provide for enhanced disclosures. The authoritative guidance will be effective for Alkame in the first quarter of fiscal 2019 and should see Alkame using a modified retrospective approach. Early adoption is permitted. Alkame is currently evaluating the effect of this new guidance on Alkame’s consolidated financial statements.

Financial Instruments: Classification and Measurement . In January 2016, the FASB issued authoritative guidance that requires equity investments that do not result in consolidation, and are not accounted for under the equity method, to be measured at fair value, and requires recognition of any changes in fair value in net income unless the investments qualify for a new practicability exception. For financial liabilities measured at fair value, the change in fair value caused by a change in instrument-specific credit risk will be required to be presented separately in other comprehensive income. The authoritative guidance will be effective for
Alkame in the first quarter of fiscal 2019. Early adoption is permitted only for the provisions related to the recognition of changes in fair value of financial liabilities caused by instrument-specific credit risk. Alkame is currently evaluating the effect of this new guidance on Alkame’s consolidated financial statements.

Inventory: In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory (Topic 330). ASU 2015-11 simplifies the accounting for the valuation of all inventory not accounted for using the last-in, first-out (“LIFO”) method by prescribing that inventory be valued at the lower of cost and net realizable value. ASU 2015-11 is effective for financial statements issued for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016 on a prospective basis. Alkame is currently evaluating the effect of this new guidance on Alkame’s consolidated financial statements.

The Company has implemented all new accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

m)   Inventory

Inventories are stated at the lower of cost or market and consist of finished goods produced in accordance with Company specifications, work-in-process as such may exist from time to time at various supplier locations that may work with Company supplied goods and materials, and raw materials that are purchased in connection with upcoming seasonal production of goods.

n) Derivative Liabilities

The Company assessed the classification of its derivative financial instruments as of December 31, 2016, which consist of convertible instruments and rights to shares of the Company’s common stock and determined that such derivatives meet the criteria for liability classification under ASC 815.

ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under

F-11


otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument subject to the requirements of ASC 815. ASC 815 also provides an exception to this rule when the host instrument is deemed to be conventional, as described.

o) Convertible Instruments

The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with professional standards for “Accounting for Derivative Instruments and Hedging Activities”.

Professional standards generally provide three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.  Professional standards also provide an exception to this rule when the host instrument is deemed to be conventional as defined under professional standards as “The Meaning of “Conventional Convertible Debt Instrument”.

The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with professional standards when “Accounting for Convertible Securities with Beneficial Conversion Features,” as those professional standards pertain to “Certain Convertible Instruments.” Accordingly, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their earliest date of redemption. The Company also records when necessary deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note.

ASC 815-40 provides that, among other things, generally, if an event is not within the entity’s control or could require net cash settlement, then the contract shall be classified as an asset or a liability.

p) Long Lived Assets

The Company follows Accounting Standards Codification subtopic 360-10, Property, Plant and Equipment (“ASC 360-10”). ASC 360-10 requires those long-lived assets and certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period. The Company evaluates the recoverability of long-lived assets based upon forecasted undiscounted cash flows. Should impairment in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset. ASC 360-10 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less costs to sell.

q) Advertising

Advertising is expensed as incurred and is included in selling costs on the accompanying consolidated statements of operations. Advertising and marketing expense for the years ended December 31, 2016 and 2015 was $4,858 and $22,728, respectively.

r) Shipping costs

Shipping costs are included in cost of goods sold and totaled $33,558 and $272,124 for the years ended December 31, 2016 and 2015, respectively.

F-12


4. Acquisition of Xtreme Technologies  

 

On April 21, 2014, we entered into a Stock Purchase Definitive Agreement (the “Agreement”) with Xtreme Technologies, Inc., an Idaho corporation (“Xtreme”). Pursuant to the terms of the Agreement, we agreed to acquire all of the issued and outstanding capital stock of Xtreme in exchange for certain consideration as set forth in the Agreement.

 

On January 16, 2015, the parties to the Agreement entered into an amendment (the “Amendment”) that changed, among other things, the Closing Date of the transaction.

 

On April 15, 2015, the parties to the Agreement entered into a second amendment (the “Second Amendment”) that changed, among other things, the 120-day time period to pay monetary consideration under the Agreement to 240 days after the Closing Date of the transaction.  

 

In accordance with the terms of the Agreement, the Amendment and the Second Amendment, we agreed to purchase all of the outstanding shares of Xtreme for the purchase price of $2,000,000, payable as follows:

 

A cash payment of $50,000 has been previously paid as a non-refundable deposit; 

The Closing Date is effective as of January 13, 2015; 

An additional cash payment of $525,000 shall be paid within two hundred and forty (240) days of the Closing Date, which, along with the initial $50,000 deposit, shall pay the obligations on Xtreme’s balance sheet;  

The balance of $1,425,000 shall be payable by the issuance of shares of the Company’s Series B Preferred Stock to be divided pro rata among the Company’s shareholders of record as of the Closing Date. The Series B Preferred Stock shall include an option to convert each share of Series B Preferred Stock into one share of the Company’s Common Stock. The Series B Preferred Stock shall be held in escrow along with the issued and outstanding shares of Xtreme’s capital stock pending the full payment of $525,000. As of the date of this report, the balance of $525,000 has been fully paid to Xtreme; and 

One of Xtreme’s previous officers and directors holds outstanding options to purchase up to 1,009,000 shares of Xtreme’s common stock at the price of $0.10 per share. At the Closing Date, pursuant to Idaho law, Xtreme shall notify this previous officer and director of his 30-day right to exercise any or all of his remaining options. If he elects to exercise any of his options within such 30-day period, the Company agrees to issue additional shares of Series B Preferred Stock in exchange for such Xtreme shares.  Xtreme notified the option holder and the 30-day period expired unanswered.  The options expired unexercised. 

 

The Amendment also requires that the Company guarantee the obligations on employment agreements for Xtreme’s key employees, namely, Keith Fuqua, Timm Ott and Casey Henry. The employment agreements with Messrs. Fuqua, Ott and Henry have the terms set forth in the following table.

 

Employee

Position

Term

Compensation

Commission

Benefits

Severance

Keith Fuqua

Operations Director

One year

$70,000 annually and annual bonus

5% on gross sales made to Walmart

Benefit plans

6 months’ severance for termination in certain instances; residual commissions for 1 year

Timm Ott

Sales and Marketing Director and Treasurer

One year

$2,700 per month salary and annual bonus

$1.00 per case of product sold

Benefit plans

6 months’ severance for termination in certain instances

Casey Henry

Manufacturing Director

One year

$4,350 per month and annual bonus

$1.00 per case of product sold

Benefit plans

6 months’ severance for termination in certain instances

 

F-13


In addition, after the Closing Date, Xtreme’s current officers and directors, namely, Jeffery J. Crandall, John N. Marcheso and Michael J. Bibin, shall continue to serve in that capacity until the $525,000 is paid in full. Our President and CEO, Robert K. Eakle and two (2) additional representatives of our company shall be appointed as directors of Xtreme and shall serve together with the other directors until the $525,000 is paid in full. In addition, Mr. Eakle shall be named as President and Chief Executive Officer of Xtreme. Until the $525,000 is paid in full, the officers and directors of Xtreme shall not make any material change in the company’s business and operations without unanimous consent of the directors. If the $525,000 is not paid in full within two hundred and forty (240) days of the Closing Date, as may be extended, then the appointments of Mr. Eakle and the other two representatives as interim officers and directors shall be terminated. Upon payment of $525,000 in full to Xtreme, all former officers and directors of Xtreme shall resign and full control of Xtreme shall be tendered to us.  Provided that certain representations are accurate, Jeffery J. Crandall, John N. Marcheso and Michael J. Bibin shall be released by us and Xtreme from any liability as officers and directors of Xtreme for their fiduciary obligations occurring prior to the Closing Date.  As of the date of this filing, the entire payment has been made.

We previously held a three-year limited exclusive distribution agreement with Xtreme for the consumer market.  We were permitted to distribute the technologically enhanced bottled water in the consumer market in the United States, Canada and Mexico.  As a result of the Agreement, Amendment, and Second Amendment, Xtreme became our wholly-owned subsidiary and we acquired the patents on the proprietary process that we believe is the most technologically advanced in water treatment systems for complete hydration. We will now assume the operations of Xtreme and continue its business of distributing technologically enhanced bottled water.

Upon closing of the acquisition, we discovered that Xtreme was operating at a loss for the prior year and that it required a substantial cash infusion.  We began a program of upgrading the production line, reorganized personnel, and began an effort to increase sales of the division so that it returns to profitability as quickly as possible.  However, as 2015 progressed, it became obvious that changes in contracts negotiated prior to our acquisition were no longer profitable and we terminated the agreements with those customers.  

Our primary objective now is to introduce, promote, aggressively market and establish channels of distribution to sell our product to a wide range of consumers, first in the United States, Canada and Mexico, and then globally.  In addition, the Company is moving in the direction of bottling or “co-packing”.

 

Alkame Holdings, Inc.

Xtreme Technologies, Inc.

Asset Acquired & Liabilities Assumed

January 14, 2015

 

 

 

 

 

2015

 

Assets

 

Liabilities

 

Impairment

Cash

$ 13,287  

 

$

 

$

Receivables

55,644  

 

 

 

 

Inventory

75,180  

 

 

 

 

Fixed Assets

91,431  

 

 

 

 

Patent Costs

  1,000,000  

 

 

 

1,000,000  

Customer List

   250,000  

 

 

 

250,000  

Trade Names

150,000  

 

 

 

150,000  

Goodwill

658,187  

 

 

 

658,187  

Accounts Payable & Accrued Liabilities

 

 

243,729  

 

 

Purchase consideration (Cash $625,000 and Series C Convertible Preferred Stock to be issued $1,425,000)

 

 

2,050,000  

 

 

 

$ 2,293,729  

 

$ 2,293,729  

 

$ 2,058,187  

As of the date of this filing, the Company has closed down this division, and written the asset values off in their entirety.  

 

F-14


5. Notes Payable, current and long-term  

 

At December 31, 2016 and 2015, notes payable consisted of the following:

 

 

December 31, 2016

 

December 31, 2015

Notes payable

$ 295,330   

 

$ 1,050,787   

Note payable Xtreme shareholders

105,500   

 

183,000   

Officer loans

16,132   

 

26,456   

Unamortized debt discount

-  

 

(35,095)  

Carrying amount

$ 416,962   

 

$ 1,225,148   

Less: current portion

(416,962)  

 

(1,200,575)  

Long-term notes payable, net

$  

 

$ 24,573   

 

Officers Loans:

 

During the years ended December 31, 2016 and 2015, the Company received $0 and $22,967, respectively, in cash loans, and made cash payments on these amounts owing totaling $10,324 and $0, respectively during the same periods. As of December 31, 2016, and 2015, the balance of the loan was $16,132 and $26,456, respectively.

 

Note Payable to Stockholders:

 

During the year ended December 31, 2013, the Company had $63,000 in expenses paid on its behalf by this shareholder and former director which was recorded as a Note. On August 1, 2013, the Company and Note Holder amended the Note by mutual agreement increasing the principal amount by an additional $10,000 for other services rendered by the former director.  The Note is unsecured, and only began accruing interest August 1, 2014 at 5% per annum on the unpaid principal thereof.  

 

During the years ended December 31, 2016 and 2015, the Company repaid $3,724 and $10,000 of the Note respectively.

 

At December 31, 2016 and 2015, the balance of the Note was $32,849 and $36,573, respectively.  

 

Notes Payable to Xtreme Shareholders:

In January 2015, an accredited investor group, EROP, filed and received approval by the courts for a 3(a)10 filing under which they acquired various debts, including the note due to the former shareholders of Xtreme Technologies, Inc. Under terms of the court order, they are able to convert the debts into common shares of the Company at a 40% discount to the market.

The original balance for the acquisition was $525,000. As of December 31, 2016, the balance outstanding is $105,500.

 

Notes Payable, others :

 

On March 29, 2013, the Company entered into a two-year promissory note agreement for $500,000. On April 8, 2013, the Company received $200,000 and on May 1, 2013, the Company received $300,000. On September 27, 2013, the note agreement was amended to include an additional advance to the Company of $250,000.  Pursuant to the agreement, the loan is secured with a general security agreement, bears interest at 10% per annum, and $500,000 was due on March 30, 2015 and $250,000 is due on September 27, 2015. The original note, and the amendment, each mature two years from date of issuance or amendment.  These notes were in technical default. Till the date of settlement of note into Series E Convertible Preferred Stock, the lender did not declare a default, and continued to forebear on collection.

 

F-15


On March 11, 2014, the Company entered into an additional two-year promissory note agreement for an additional $100,000 from the same investor group, on the same terms as outlined above.

The Company paid 10% of proceeds from $850,000 of the long-term notes payable as financing cost of $85,000 to a consultant. The Company amortizes this cost over the term of the note payable.

On May 10, 2016, we entered into a Debt Exchange Agreement pursuant to which we converted $1,076,125 in debt and accrued interest into 1,250,000 shares of our newly created Series E Preferred Stock. These shares were not issued as of December 31, 2016.

A copy of the Debt Exchange Agreement is attached to the Current Report on Form 8-K as Exhibit 10.1 filed on May 11, 2016.

During the years ended December 31, 2016 and 2015, the Company charged to operations $5,291 and $81,194 as amortization of deferred financing costs, respectively. As of December 31, 2016, and 2015, remaining balance in deferred financing cost of $222 and $5,513, respectively is presented as part of other assets.

In July 2015, the Company borrowed $70,000 from an accredited investor group on a term loan. The note carries interest at 15% per annum and requires repayment of a total of $98,000 through daily payments of $560.  As of December 31, 2016, the balance outstanding is $63,840.

In July 2015, the Company borrowed $25,000 from an accredited investor group on a term loan. The note carries prepaid interest of 10% of the amount borrowing.  As of December 31, 2016, the balance outstanding is $22,554.

In August 2015, the Company borrowed $50,000 from an accredited investor group on a term loan. The note carries interest at 15% per annum and requires repayment of a total of $74,500 through daily payments of $899.  As of December 31, 2016, the balance outstanding is $49,100.

In January 2016, the Company borrowed $4,000 from an accredited investor on a short-term loan.  The note carries interest at 10% per annum and is due on demand.  In May 2016, the Company repaid $500 of the loan.

Beginning in April 2016, the Company borrowed a series of short-term working capital loans from an accredited investor totaling $100,000 and carries interest at 10% per annum.  The loans are secured by accounts receivable and requires repayment in 18 months. As of December 31, 2016, the balance outstanding is $100,000.

 

6. Convertible debt  

 

At December 31, 2016 and 2015 convertible notes and debentures consisted of the following:

 

 

December 31, 2016

 

December 31, 2015

Convertible notes payable

$ 744,470   

 

$ 635,223   

Unamortized debt discount

(109,774)  

 

(53,258)  

Carrying amount

$ 634,696   

 

$ 581,965   

Less: current portion

(634,696)  

 

(552,479)  

Long-term convertible notes, net

$  

 

$ 29,486   

 

At various times, the Company entered into Convertible Promissory Notes on various terms accredited institutional investors.  The debentures are convertible at the discounts of between fifty percent (50%) and sixty percent (60%) of the market price of the Company’s Common Stock determined based on the lowest trading price in a twenty (20) to twenty-five (25) day period prior to the date of conversion or the average of a three (3) period closing price of the Company’s stock.  Some notes were issued with an original issue discount which was charged to current period operations as interest expense during the year of inception.

 

F-16


The following table summarizes the debt discounts recorded on convertible debt in connection with the above convertible debentures.

 

 

December 31, 2016

 

December 31, 2015

Debt Discount beginning balance

$ 53,258   

 

$ 412,542   

Additions

101,026   

 

353,834   

Amortization

(44,510)  

 

(713,118)  

Ending Balance

$ 109,774   

 

$ 53,258   

 

 

During the year ended December 31, 2016, the Company issued 479,566,257 shares of its common stock valued at $278,820, upon conversion of $88,583 principal and $2,728 interest and recorded a loss on extinguishment of debt of $25,372.

 

The Company identified embedded derivatives related to the Convertible Promissory Notes entered into in the years ended December 31, 2014 and 2015.  These embedded derivatives included certain conversion features as described in the preceding paragraph. The accounting treatment of derivative financial instruments requires that the Company record the fair value of the derivatives as of the inception date of the Convertible Promissory Note and to adjust the fair value as of each subsequent balance sheet date. At the inception of the Convertible Promissory Notes, the Company determined a fair value of the embedded derivative. The fair value of the embedded derivative was determined using the Black-Scholes Model based on the assumptions outlined in the following table: 

 

F-17


Summary of Convertible Debt and Derivative Liabilities

12/31/2016

 

 

 

 

Black-Scholes Assumptions

Derivative

 

Black-Scholes Assumptions

Derivative

 Derivative

 

Black-Scholes Assumptions

Derivative

 Derivative

 

 

 

Full

Inception

Liability

Note

12/31/2015

Liability

Liability

Note

12/31/2016

Liability

Liability

Date

Original Amount

Term (Months)

Conv.        Y / N

Dividend Yield

Volatility

Risk Free Rate

Inception

Balance 12/31/15

Dividend Yield

Volatility

Risk Free Rate

Balance 12/31/2015

Adjustment 12/31/2015

Balance 12/31/16

Dividend Yield

Volatility

Risk Free Rate

Balance 12/31/2016

Adjustment 12/31/2016

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

08/06/14

$ 82,500  

12  

Y

0.00%  

105.00%  

0.48%  

$ 190,451  

$ -  

N/A

N/A

N/A

$ -  

$ -  

$

N/A

N/A

N/A

$ -  

$  

08/06/14

$ 68,000  

9  

Y

0.00%  

105.00%  

0.48%  

$ 94,657  

$ -  

N/A

N/A

N/A

$ -  

$ -  

$ -  

N/A

N/A

N/A

$ -  

$  

08/11/14

$ 45,000  

5  

Y

0.00%  

111.00%  

0.05%  

$ 131,493  

$ -  

N/A

N/A

N/A

$ -  

$ -  

$ -  

N/A

N/A

N/A

$ -  

$  

09/04/14

$ 42,500  

9  

Y

0.00%  

131.00%  

0.48%  

$ 52,597  

$ -  

N/A

N/A

N/A

$ -  

$ -  

$

N/A

N/A

N/A

$ -  

$  

09/05/14

$ 52,500  

12  

 

0.00%  

166.00%  

0.10%  

$ 578,343  

$ 52,500  

0.00%  

279.00%

0.16%  

$ 89,087  

$ 1,089   

$ 57,750  

0.00%  

459.37%  

0.51%  

$ 79,308  

$ 9,779   

09/11/14

$ 56,250  

9  

Y

0.00%  

240.00%  

0.11%  

$ 300,489  

$ -  

 0.00%

279.00%

 0.16%

$ -  

$ 84,133   

$ -  

N/A

N/A

N/A

$ -  

$  

10/24/14

$ 55,000  

12  

 

0.00%  

260.00%  

0.11%  

$ 162,550  

$ 55,000  

0.00%  

279.00%

0.16%  

$ 79,536  

$ 5,679   

$ 60,500  

0.00%  

459.37%  

0.51%  

$ 144,168  

$ (64,632)  

10/27/14

$ 33,000  

24  

 

0.00%  

260.00%  

0.41%  

$ 100,870  

$ 33,000  

0.00%  

279.00%

0.65%  

$ 70,237  

$ (12,490)  

$ 27,000  

0.00%  

459.37%  

0.51%  

$ 36,294  

$ 33,943   

10/29/14

$ 55,000  

12  

 

0.00%  

260.00%  

0.11%  

$ 142,870  

$ 55,000  

0.00%  

279.00%

0.16%  

$ 95,625  

$ (10,134)  

$ 57,750  

0.00%  

459.37%  

0.51%  

$ 133,296  

$ (37,671)  

11/12/14

$ 75,000  

12  

 

0.00%  

261-275%  

0.14%  

$ 324,627  

$ 75,000  

0.00%  

279.00%

0.16%  

$ 98,343  

$ 96,998   

$ 102,344  

0.00%  

459.37%  

0.51%  

$ 217,101  

$ (119,428)  

12/16/14

$ 39,772  

24  

 

0.00%  

275.00%  

0.58%  

$ 85,288  

$ 38,889  

0.00%  

279.00%

0.65%  

$ 84,713  

$ (14,726)  

$ 31,163  

0.00%  

459.37%  

0.51%  

$ 41,801  

$ 42,912   

01/22/15

$ 75,000  

12  

 

0.00%  

335.00%  

0.17%  

$ 210,982  

$ 75,000  

0.00%  

279.00%

0.16%  

$ 121,370  

$ 89,612   

$ 74,949  

0.00%  

459.37%  

0.51%  

$ 166,429  

$ (45,059)  

01/29/15

$ 28,000  

9  

Y

0.00%  

336.00%  

0.11%  

$ 46,247  

$ -  

0.00%  

280.00%

0.00%  

$ -  

$ 46,247   

$ -  

0.00%  

459.37%  

0.51%  

$ -  

$  

02/09/15

$ 108,000  

12  

 

0.00%  

336.00%  

0.11%  

$ 181,521  

$ 108,000  

0.00%  

279.00%

0.14%  

$ 139,323  

$ 42,197   

$ 108,000  

0.00%  

459.37%  

0.51%  

$ 335,279  

$ (195,956)  

02/10/15

$ 22,000  

24  

 

0.00%  

336.00%  

0.11%  

$ 41,170  

$ 22,000  

0.00%  

279.00%

0.65%  

$ 48,922  

$ (7,751)  

$ 22,000  

0.00%  

459.37%  

0.51%  

$ 32,860  

$ 16,062   

02/19/15

$ 35,000  

12  

 

0.00%  

336.00%  

0.11%  

$ 53,829  

$ 35,000  

0.00%  

279.00%

0.14%  

$ 58,999  

$ (5,170)  

$ 38,500  

0.00%  

459.37%  

0.51%  

$ 135,174  

$ (76,175)  

02/25/15

$ 33,333  

24  

 

0.00%  

340.00%  

0.10%  

$ 61,358  

$ 33,333  

0.00%  

279.00%

0.65%  

$ 74,476  

$ (13,118)  

$ 33,333  

0.00%  

459.37%  

0.51%  

$ 52,378  

$ 22,098   

03/13/15

$ 52,500  

8  

 

0.00%  

343.00%  

0.11%  

$ 73,432  

$ 52,500  

0.00%  

279.00%

0.16%  

$ 86,004  

$ (12,572)  

$ 57,750  

0.00%  

459.37%  

0.51%  

$ 58,562  

$ 27,442   

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$ 958,355  

 

 

 

 

 

$ 2,832,774  

$ 635,223  

 

 

 

$ 1,046,635  

$ 289,994   

$ 671,039  

 

 

 

$ 1,432,650  

$ (386,685)  

F-18


7. Fair Value of Financial Instruments  

 

ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value: 

   

Level 1 - Quoted prices in active markets for identical assets or liabilities.

 

Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.

 

Level 3 - Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.

   

To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed is determined based on the lowest level input that is significant to the fair value measurement.  

 

Items recorded or measured at fair value on a recurring basis in the accompanying consolidated financial statements consisted of the following items as of December 31, 2016:

 

 

 

 

Fair Value Measurements at December 31, 2016 using:

 

December 31,
2016

 

Quoted Prices in Active
Markets for
Identical
Assets
(Level 1)

 

Significant
Other
Observable
Inputs
(Level 2)

 

Significant
Unobservable Inputs
(Level 3)

Liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Derivative Liabilities

$ 1,432,650

$

-

$

-

 

$ 1,432,650

 

 

 

 

 

Fair Value Measurements at December 31, 2015 using:

 

December 31,
2015

 

Quoted Prices in Active
Markets for
Identical
Assets
(Level 1)

 

Significant
Other
Observable
Inputs
(Level 2)

 

Significant
Unobservable Inputs
(Level 3)

Liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Derivative Liabilities

$ 1,046,635

$

-

$

-

 

$ 1,046,635

F-19


The debt and warrant derivative liabilities are measured at fair value using quoted market prices and estimated volatility factors based on historical prices for the Company’s common stock and are classified within Level 3 of the valuation hierarchy. 

  

The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities as of December 31, 2016:

 

 

 

Derivative Liability

Balance, December 31, 2015

 

$

1,046,635   

Extinguishment of derivative liability upon conversion of debt

 

 

(188,408)   

Change in fair value of derivative liabilities

 

 

574,423  

Balance, December 31, 2016

 

$

1,432,650   

 

 

8. Prepaid Assets  

 

During the year ended December 31, 2013, the Company entered into various agreements for future services such as financial management, radio and news spots highlighting the use of the Company’s product, and news release services.  The contracts ranged in length from six months to two years.

 

At their inception, the Company issued common stock in exchange for these services.  The Company treats the cost of the stock issuance as a prepaid expense to be amortized over the life of the agreement.

 

Balance at

December 31, 2015

Amortized in 2016

Balance at

December 31, 2016

Current Asset

Long Term Asset

$7,000

$ 5,000

$ 2,000

$ 2,000

$ 0

 

 

9. Related Party Transactions  

 

During the years ended December 31, 2016 and 2015, the Company received $0 and $22,967, respectively, in cash loans from its president, and made cash payments on these amounts owing totaling $10,324 and $0, respectively during the same periods. As of December 31, 2016, and 2015, the Company owed $16,132 and $26,456 respectively, to its President.  The amount owing is unsecured, non-interest bearing and due on demand.

On December 9, 2015, the Company issued 1,000,000 Series D Convertible Preferred shares each as compensation to its CEO and Kaufman & Associates a consultant.

As of December 31, 2016, and 2015, the Company owes its president $360,000 and $240,000, respectively, of accrued compensation.

 

As of December 31, 2016, and 2015, the Company owes $307,270 and $213,480, respectively to Kaufman & Associates (holding more than 5% shares of the Company) in connection with a consulting agreement and included in accrued compensation on the balance sheet.

 

F-20


10. Stockholders’ Deficit  

 

a)         Authorized  

      

Authorized capital stock consists of: 

 

· 5,500 ,000,000 common shares with a par value of $0.001 per share; and

 

· 10 0,000,000 preferred shares with a par value of $0.001 per share;

o The Company has designated 12,000,000 shares as Series A Convertible Preferred Series Stock. Each share of Series A Preferred Stock is convertible into fifty (50) shares of Common Stock.  

o The Company has designated 70,000,000 shares as Series B Convertible Preferred Series Stock.  Each share of Series B Preferred Stock is convertible into one (1) share of Common Stock. 

o The Company has designated 10,000,000 shares as Series C Convertible Preferred Series Stock.  Each share of Series C Preferred Stock is convertible into $1.00 of Common Shares at the market price on the date of conversion. 

o The Company has designated 4,000,000 shares as Series D Convertible Preferred Series Stock. Each share of Series D Preferred Stock is convertible into ten (10) shares of Common Stock. See additional description and preferences under “Series D Preferred Stock” below. 

o The Company has designated 1,250,000 shares as Series E Convertible Preferred Series Stock, par value $1.00 per share. Each share of Series E Preferred Stock is convertible into common stock, subject to adjustments, at a conversion price equal to a 50% discount to the VWAP per share for the 5 trading days prior to written notice of conversion. See additional description and preferences under “Series E Preferred Stock” below. 

 

Increase in authorized shares

 

On January 24, 2014, the Company filed a Certificate of Amendment to the Company’s Articles of Incorporation (the “Certificate of Amendment”) with the Nevada Secretary of State. The Certificate of Amendment amends Article III of the Company’s Articles of Incorporation to authorize the issuance of up to one hundred million (100,000,000) shares of Preferred Stock, par value $0.001 per share, which may be issued in one or more series, with such rights, preferences, privileges and restrictions as shall be fixed by the Company’s Board of Directors from time to time. As a result of the Certificate of Amendment, we now have one billion (1,000,000,000) authorized shares, par value $0.001 per share, consisting of two classes designated as “Common Stock” and “Preferred Stock.” The total number of shares of Common Stock that we have authority to issue is nine hundred million (900,000,000) shares and the total number of shares of Preferred Stock that we have authority to issue is one hundred million (100,000,000) shares. The Company’s Board of Directors and a majority of our shareholders approved the Certificate of Amendment.

 

On May 10, 2016, we filed with the Secretary of State of the State of Nevada a Certificate of Amendment to the Articles of Incorporation to increase the authorized shares of Common Stock of our company (the “Amendment”). The Amendment authorizes us to issue 5,500,000,000 shares of Common Stock, par value $0.001 per share. The Amendment did not increase our authorized shares of Preferred Stock.

 

F-21


Series A Preferred Stock:

 

1. Designation and Rank.  

This series of Preferred Stock shall be designated and known as “Series A Preferred Stock.” The number of shares constituting the Series A Preferred Stock shall be twelve million (12,000,000) shares. Except as otherwise provided herein, the Series A Preferred Stock shall, with respect to rights on liquidation, winding up and dissolution, rank pari passu to the common stock, par value $0.001 per share (the “Common Stock”).

 

2. Dividends.  

 

The holders of shares of Series A Preferred Stock have no dividend rights except as may be declared by the Board in its sole and absolute discretion, out of funds legally available for that purpose.

 

3. Liquidation Preference.

(a) In the event of any dissolution, liquidation or winding up of the Corporation (a “Liquidation”), whether voluntary or involuntary, the Holders of Series A Preferred Stock shall be entitled to participate in any distribution out of the assets of the Corporation on an equal basis per share with the holders of the Common Stock.

 

(b) A sale of all or substantially all of the Corporation’s assets or an acquisition of the Corporation by another entity by means of any transaction or series of related transactions (including, without limitation, a reorganization, consolidated or merger) that results in the transfer of fifty percent (50%) or more of the outstanding voting power of the Corporation (a “Change in Control Event”), shall not be deemed to be a Liquidation for purposes of this Designation.

 

4. Voting.

 

The holders of Series A Preferred Stock shall have the right to cast one hundred (100) votes for each share held of record on all matters submitted to a vote of holders of the Corporation’s common stock, including the election of directors, and all other matters as required by law. There is no right to cumulative voting in the election of directors. The holders of Series A Preferred Stock shall vote together with all other classes and series of common stock of the Corporation as a single class on all actions to be taken by the common stock holders of the Corporation except to the extent that voting as a separate class or series is required by law.

 

On October 7, 2013, the Company filed an Amendment to the Certificate of Designation of the Series A Preferred Stock of the Company with the Secretary of State of Nevada. Paragraph 1 of the Certificate of Designation was amended to change the name of the Series A Preferred Stock to Series A Convertible Preferred Stock and to increase the number of authorized Series A Convertible Preferred Stock from 10,000,000 shares to 12,000,000 shares. The Company also added a new Paragraph 5 to include conversion rights of the Series A Convertible Preferred Stock. Each share of Series A Convertible Preferred Stock may convert into fifty (50) shares of common stock of the Company.

 

Series B Convertible Preferred Stock

 

On January 24, 2014, pursuant to Article III of our Articles of Incorporation, the Company’s Board of Directors voted to designate a class of preferred stock entitled Series B Preferred Stock, consisting of up to seventy million (70,000,000) shares, par value $0.001. Under the Certificate of Designation, holders of Series B Preferred Stock will participate on an equal basis per-share with holders of our common stock and Series A Preferred Stock in any distribution upon winding up, dissolution, or liquidation. Holders of Series B Preferred Stock are entitled to convert each share of Series B Preferred Stock into one (1) share of common stock. Holders of Series B Preferred Stock are also entitled to vote together with the holders of our common stock and Series A Preferred Stock on all matters submitted to shareholders at a rate of one (1) vote for each share held.

 

The rights of the holders of Series B Preferred Stock are defined in the relevant Certificate of Designation filed with the Nevada Secretary of State on January 24, 2014.

 

F-22


Series C Convertible Preferred Stock

 

On January 24, 2014, pursuant to Article III of our Articles of Incorporation, the Company’s Board of Directors voted to designate a class of preferred stock entitled Series C Preferred Stock, consisting of up to ten million (10,000,000) shares, par value $0.001. Under the Certificate of Designation, holders of Series C Preferred Stock will be entitled to receive the Stated Value per share ($1.00) in any distribution upon winding up, dissolution, or liquidation. Holders of Series C Preferred Stock are entitled to convert such number of shares of Common Stock equal to the quotient of the Stated Value per share divided by the closing price of our common stock on the day of conversion. Holders of Series C Preferred Stock are also entitled to vote together with the holders of our common stock, Series A Preferred Stock and Series B Preferred Stock on all matters submitted to shareholders at a rate of one (1) vote for each share held.

 

The rights of the holders of Series C Preferred Stock are defined in the relevant Certificate of Designation filed with the Nevada Secretary of State on January 24, 2014.

 

Series D Convertible Preferred Stock

 

On December 2, 2015, pursuant to Article III of our Articles of Incorporation, the Company’s Board of Directors voted to designate a class of preferred stock entitled Series D Preferred Stock, consisting of up to four million (4,000,000) shares, par value $0.001. Under the Certificate of Designation, holders of Series D Preferred Stock will be entitled to receive the value at which they were issued ($0.003 per share) in any distribution upon winding up, dissolution, or liquidation.  Holders of Series D Preferred Stock are entitled to convert such number of shares to Common Stock equal to the number of Series D Preferred Stock held multiplied by ten (10).  Holders of Series D Preferred Stock are also entitled to vote together with the holders of our common stock, Series A Preferred Stock and Series B Preferred Stock on all matters submitted to shareholders at a rate of twenty-five thousand (25,000) votes for each share held.

 

The rights of the holders of Series D Preferred Stock are defined in the relevant Certificate of Designation filed with the Nevada Secretary of State on December 2, 2015.

 

Series E Convertible Preferred Stock

 

On May 10, 2016, pursuant to Article III of our Articles of Incorporation, our Board of Directors voted to designate a class of preferred stock entitled Series E Preferred Stock, consisting of up to 1,250,000 shares. The Certificate of Designation for the Series E Preferred Stock contains the following features:

 

1. No voting rights; 

2. Dividends on an as converted basis along with the holders of common stock as and when declared by our Board of Directors; 

3. Rank junior to all other issued and outstanding shares of preferred stock in any liquidation; 

4. A liquidation preference over common stock equal to the greater of: $1.00 per share and any unpaid dividends; and the as converted amount; 

5. Convertible into common stock, subject to adjustments, at a conversion price equal to a 50% discount to the VWAP per share for the 5 trading days prior to written notice of conversion; 

6. Redeemable by us at $1.00 per share; and 

7. Protective provisions requiring prior approval to: issue additional shares of preferred stock in an already existing and designated series; liquidate the business; pay dividends; or take any other action under Nevada law that would require prior approval of the holders of Series E Preferred Stock. 

  

The full rights afforded to the holders of Series E Preferred Stock are defined in the relevant Certificate of Designation filed with the Nevada Secretary of State on May 10, 2016, attached to the Current Report on Form 8-K as Exhibit 3.1 filed on May 11, 2016.

 

F-23


b)           Share Issuances  

 

As of December 31, 2016, and 2015, there were 1,178,551,804 and 198,485,547 shares of common stock issued and outstanding, respectively.  

 

2016:

 

On February 9, 2016, the Company issued 4,500,000 common shares upon conversion of $7,020 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00156 per share.

 

On February 12, 2016, the Company issued 5,000,000 common shares upon conversion of $6,750 of convertible debt.  The shares were issued at a price of $0.00135 per share.

 

On February 16, 2016, the Company issued 5,454,545 common shares upon conversion of $7,500 of convertible debt.  The shares were issued at a price of $0.00138 per share.

 

On February 16, 2016, the Company issued 2,027,396 common shares upon conversion of $2,686 of convertible debt and accrued interest.  The shares were issued at a price of $0.00132 per share.

 

On February 17, 2016, the Company issued 10,226,900 common shares upon conversion of $8,949 of convertible debt.  The shares were issued at a price of $0.00088 per share.

 

On February 18, 2016, the Company issued 5,952,381 common shares upon conversion of $5,000 of convertible debt.  The shares were issued at a price of $0.00084 per share.

 

On February 22, 2016, the Company issued 18,552,879 common shares upon conversion of $10,000 of convertible debt.  The shares were issued at a price of $0.00054 per share.

 

On February 22, 2016, the Company issued 11,904,762 common shares upon conversion of $5,000 of convertible debt.  The shares were issued at a price of $0.00042 per share.

 

On February 22, 2016, the Company issued 9,904,429 common shares upon conversion of $4,160 of convertible debt.  The shares were issued at a price of $0.00042 per share.

 

On February 23, 2016, the Company issued 7,500,000 common shares upon conversion of $2,625 of convertible debt.  The shares were issued at a price of $0.00035 per share.

 

On February 24, 2016, the Company issued 21,636,364 common shares upon conversion of $5,950 of convertible debt.  The shares were issued at a price of $0.000275 per share.

 

On February 25, 2016, the Company issued 9,901,698 common shares upon conversion of $2,099 of convertible debt and accrued interest.  The shares were issued at a price of $0.00021 per share.

 

On February 26, 2016, the Company issued 10,226,909 common shares upon conversion of $818 of convertible debt.  The shares were issued at a price of $0.00008 per share.

 

On February 29, 2016, the Company issued 23,787,879 common shares upon conversion of $3,925 of convertible debt.  The shares were issued at a price of $0.00016 per share.

 

On February 29, 2016, the Company issued 7,500,000 common shares upon conversion of $1,125 of convertible debt.  The shares were issued at a price of $0.00015 per share.

 

F-24


On March 1, 2016, the Company issued 9,904,429 common shares upon conversion of $1,189 of convertible debt.  The shares were issued at a price of $0.00012 per share.

 

On March 2, 2016, the Company issued 23,852,814 common shares upon conversion of $2,755 of convertible debt.  The shares were issued at a price of $0.00012 per share.

 

On March 7, 2016, the Company issued 21,715,522 common shares upon conversion of $1,194 of convertible debt.  The shares were issued at a price of $0.00005 per share.

 

On March 7, 2016, the Company issued 2,102,660 common shares upon conversion of $116 of convertible debt.  The shares were issued at a price of $0.000055 per share.

 

On March 7, 2016, the Company issued 23,818,182 common shares upon conversion of $1,310 of convertible debt.  The shares were issued at a price of $0.000055 per share.

 

On March 8, 2016, the Company issued 9,725,791 common shares upon conversion of $195 of convertible debt.  The shares were issued at a price of $0.00002 per share.

 

On March 10, 2016, the Company issued 9,904,429 common shares upon conversion of $594 of convertible debt.  The shares were issued at a price of $0.00006 per share.

 

On March 10, 2016, the Company issued 23,818,182 common shares upon conversion of $1,310 of convertible debt.  The shares were issued at a price of $0.000055 per share.

 

On March 11, 2016, the Company issued 9,725,000 common shares upon conversion of $195 of convertible debt.  The shares were issued at a price of $0.00002 per share.

 

On March 15, 2016, the Company issued 9,904,429 common shares upon conversion of $594 of convertible debt.  The shares were issued at a price of $0.00006 per share

 

On March 16, 2016, the Company issued 23,818,182 common shares upon conversion of $1,310 of convertible debt.  The shares were issued at a price of $0.00005 per share.

 

On March 17, 2016, the Company issued 16,318,490 common shares upon conversion of $865 of convertible debt and accrued interest.  The shares were issued at a price of $0.00005 per share.

 

On March 18, 2016, the Company issued 9,904,429 common shares upon conversion of $594 of convertible debt.  The shares were issued at a price of $0.00006 per share

 

On March 23, 2016, the Company issued 20,500,000 common shares upon conversion of $12,300 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.0006 per share.

 

On March 23, 2016, the Company issued 9,904,429 common shares upon conversion of $594 of convertible debt.  The shares were issued at a price of $0.00006 per share.

 

On May 24, 2016, the Company issued 28,800,000 common shares upon conversion of $6,912 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00024 per share.

 

On June 16, 2016, the Company issued 30,250,000 common shares upon conversion of $3,630 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00012 per share.

 

F-25


On July 11, 2016, the Company issued 31,750,000 common shares upon conversion of $3,810 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00012 per share.

 

On July 25, 2016, the Company issued 33,300,000 common shares upon conversion of $3,996 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00012 per share.

 

On September 13, 2016, the Company issued 35,000,000 common shares upon conversion of $4,200 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00012 per share.

 

On October 13, 2016, the Company issued 36,500,000 common shares upon conversion of $4,380 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00012 per share.

 

On October 16, 2016, the Company issued 36,533,396 common shares upon conversion of $1,936 of convertible debt and accrued interest.  The shares were issued at a price of $0.000053 per share.

 

On October 25, 2016, the Company issued 38,500,000 common shares upon conversion of $4,620 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00012 per share.

 

On October 27, 2016, the Company issued 36,687,169 common shares upon conversion of $3,889 of convertible debt and accrued interest.  The shares were issued at a price of $0.00011 per share.

 

On October 28, 2016, the Company issued 42,300,000 common shares upon conversion of $7,614 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00018 per share.

 

On November 1, 2016, the Company issued 46,200,000 common shares upon conversion of $8,316 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00018 per share.

 

On November 1, 2016, the Company issued 19,827,273 common shares upon conversion of $2,181 of convertible debt.  The shares were issued at a price of $0.00011 per share.

 

On November 7, 2016, the Company issued 32,525,312 common shares upon conversion of $3,903 of convertible debt and accrued interest.  The shares were issued at a price of $0.00012 per share.

 

On November 14, 2016, the Company issued 48,500,000 common shares upon conversion of $29,100 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.0006 per share.

 

On November 18, 2016, the Company issued 50,900,000 common shares upon conversion of $12,216 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00024 per share.

 

On December 7, 2016, the Company issued 53,500,000 common shares upon conversion of $9,630 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00018 per share.

 

F-26


2015:

 

On January 12, 2015, the Company issued 3,600,000 common shares upon conversion of $69,336 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.01926 per share.

 

On February 4, 2015, the Company issued 3,000,000 common shares upon conversion of $54,000 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.018 per share.

 

On February 9, 2015, the Company issued 2,000,000 common shares upon conversion of $36,210 of convertible debt.  The shares were issued at a price of $0.01806 per share.

 

On February 17, 2015, the Company issued 1,428,571 common shares upon conversion of $25,000 of convertible debt.  The shares were issued at a price of $0.0175 per share.

 

On February 20, 2015, the Company issued 3,500,000 common shares upon conversion of $56,910 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.01626 per share.

 

On February 23, 2015, the Company issued 1,481,481 common shares upon conversion of $20,000 of convertible debt.  The shares were issued at a price of $0.0135 per share.

 

On February 24, 2015, the Company issued 1,750,000 common shares upon conversion of $17,850 of convertible debt.  The shares were issued at a price of $0.0102 per share.

 

On February 25, 2015, the Company issued 2,500,000 common shares upon conversion of $32,500 of convertible debt.  The shares were issued at a price of $0.013 per share.

 

On February 25, 2015, the Company issued 2,686,667 common shares upon conversion of $22,837 of convertible debt and accrued interest.  The shares were issued at a price of $0.0085 per share.

 

On February 26, 2015, the Company issued 1,518,333 common shares upon conversion of $18,220 of convertible debt and accrued interest.  The shares were issued at a price of $0.012 per share.

 

On March 5, 2015, the Company issued 1,800,000 common shares upon conversion of $13,500 of convertible debt.  The shares were issued at a price of $0.0075 per share.

 

On March 10, 2015, the Company issued 4,500,000 common shares upon conversion of $31,860 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00708 per share.

 

On March 12, 2015, the Company issued 3,424,658 common shares upon conversion of $25,000 of convertible debt.  The shares were issued at a price of $0.0073 per share.

 

On March 12, 2015, the Company issued 3,653,013 common shares upon conversion of $25,863 of convertible debt.  The shares were issued at a price of $0.00708 per share.

 

On March 12, 2015, the Company issued 4,955,500 common shares upon conversion of $33,797 of convertible debt and accrued interest.  The shares were issued at a price of $0.00682 per share.

 

On March 12, 2015, the Company issued 1,736,111 common shares upon conversion of $12,500 of convertible debt.  The shares were issued at a price of $0.0072 per share.

 

F-27


On March 16, 2015, the Company issued 1,000,000 common shares upon conversion of $6,700 of convertible debt and accrued interest.  The shares were issued at a price of $0.0067 per share.

 

On March 18, 2015, the Company issued 5,000,000 common shares upon conversion of $21,600 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00432 per share.

 

On March 26, 2015, the Company issued 5,697,909 common shares upon conversion of $19,886 of convertible debt and accrued interest.  The shares were issued at a price of $0.00349 per share.

 

On March 30, 2015, the Company issued 2,106,545 common shares upon conversion of $4,880 of convertible debt and accrued interest.  The shares were issued at a price of $0.00231 per share.

 

On March 31, 2015, the Company issued 6,600,000 common shares upon conversion of $15,048 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00228 per share.

 

On April 15, 2015, the Company issued 6,000,000 common shares upon conversion of $14,400 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.0024 per share.

 

On May 4, 2015, the Company issued 7,400,000 common shares upon conversion of $29,748 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00402 per share.

 

On June 2, 2015, the Company issued 5,118,865 common shares upon conversion of $30,713 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.006 per share.

 

On June 17, 2015, the Company issued 5,000,000 common shares upon conversion of $39,900 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00798 per share.

 

On August 5, 2015, the Company issued 8,000,000 common shares upon conversion of $26,880 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00336 per share.

 

On August 25, 2015, the Company issued 7,000,000 common shares upon conversion of $21,000 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.003 per share.

 

On September 28, 2015, the Company issued 5,482,288 common shares upon conversion of $10,855 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00198 per share.

 

On September 30, 2015 the Company recorded additional $24,718 as value of shares sold in payment of debt in excess of value in connection with the August and September 2015 settlements under the Section 3(a)10 of the Rules of the SEC.

 

On November 12, 2015, the Company issued 9,000,000 common shares upon conversion of $17,280 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.00192 per share.

 

F-28

On December 9, 2015, the Company issued 2,000,000 Series D Convertible Preferred shares as compensation to its CEO and a consultant.  The shares were issued at a price of $0.003 per common share into which they are convertible.

 

On December 29, 2015, the Company issued 7,500,000 common shares upon conversion of $18,000 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.0024 per share.

 

On December 31, 2015 the Company recorded additional $21,056 as value of shares sold in payment of debt in excess of value in connection with the November and December 2015 settlements under the Section 3(a)10 of the Rules of the SEC.

 

c) Warrants

 

The following table summarizes the changes in warrants outstanding and related prices for the shares of the Company’s common stock issued to shareholders at December 31, 2016:

 

Exercise
Price

 

Number
Outstanding

 

Warrants
Outstanding
Weighted Average
Remaining
Contractual
Life (years)

 

Weighted
Average
Exercise price

 

Number
Exercisable

 

Warrants 
Exercisable
Weighted
Average
Exercise Price

$ 0.24  

 

1,587,302  

 

2.87  

 

$ 0.24  

 

1,587302  

 

$ 0.24  

 

Transactions involving the Company’s warrant issuance are summarized as follows:

 

 

Number of

Shares

 

Weighted Average

Price Per Share

Outstanding at December 31, 2014

1,587,302  

 

$ 0.24  

        Issued

 

 

 

        Exercised

 

 

 

        Expired

 

 

 

Outstanding at December 31, 2015

1,587,302  

 

$ 0.24  

         Issued

 

 

 

        Exercised

 

 

 

        Expired

 

 

 

Outstanding at December 31, 2016

1,587,302  

 

$ 0.24  

 

Warrants outstanding as of December 31, 2016, as disclosed in the above table, have an intrinsic value of $0.

 

 

11. Income Taxes  

 

Deferred income tax assets as of December 31, 2016 of $3,927,500 resulting from net operating losses and future amortization deductions, have been fully offset by valuation allowances.  The valuation allowances have been established equal to the full amounts of the deferred tax assets, as the Company is not assured that it is more likely than not that these benefits will be realized.

 

F-29

Reconciliation between the statutory United States corporate income tax rate (34% for 2016 and 2015) and the effective income tax rates based on continuing operations is as follows:

 

Year ended December 31,

2016

 

2015

Expected Federal Income tax benefit

$  (653,400)  

 

$ (1,532,300)  

Expected State Income Tax benefit, net

             (126,800)

 

            (297,500)

Impairment of intangible assets

                         -

 

             783,800 

Amortization of beneficial conversion feature

                 18,100

     

             290,000

Change in fair value of derivative liability

               233,200

 

           (117,700)

Other permanent differences

                   6,300

 

               41,100

Change in valuation allowance

 522,600  

 

             832,600 

  Total

$  

 

$  

 

 

Components of deferred tax assets were approximately as follows:

 

  As at December 31,

2016

 

2015

 Net operating loss carry forward

$ 3,524,100   

 

$ 3,290,630   

Accrued liabilities

403,400   

 

114,300  

Valuation allowance

(3,927,500)  

 

(3,404,900)  

Total  

$  

 

$  

 

At December 31, 2016, the Company has available net operating losses of approximately $8,680,000 which may be carried forward to apply against future taxable income. These losses will expire in 2036. Deferred tax assets related to these losses have not been recorded due to uncertainty regarding their utilization.

 

The provisions of ASC 740 require companies to recognize in their financial statements the impact of a tax position if that position is more likely than not to be sustained upon audit, based upon the technical merits of the position. ASC 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken on a tax return. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods and disclosure.

 

Management does not believe that the Company has any material uncertain tax positions requiring recognition or measurement in accordance with the provisions of ASC 740. Accordingly, the adoption of these provisions of ASC 740 did not have a material effect on the Company’s financial statements. The Company’s policy is to record interest and penalties on uncertain tax positions, if any, as income tax expense.

 

The Company has not filed its applicable Federal and State tax returns for the years ended December 31, 2012, 2013, 2014, 2015, and 2016 and may be subject to penalties for noncompliance. The Company has filed an extension for the 2017 filing and is retaining a tax accountant to complete the necessary filings.

 

As a result of stock issuances in 2013, 2015, and 2016 the future utilization of the Company’s net operating losses is likely limited pursuant to Internal Revenue Code section 382.  The deferred tax asset derived from these tax loss carryforwards have been included in consolidated deferred tax assets - net operating loss carryforwards, and a full valuation allowance has been established since it is not more likely than not that such benefits will be recovered.

 

F-30


 

12. Inventory  

Inventory

 

Inventories are stated at cost, with cost being determined on the First in First Out (FIFO) cost method. Inventory costs include material, import control costs, unpacking at the warehouse facility, and freight charges. The Company provides inventory allowances based on excess and obsolete inventories determined primarily by future demand forecasts.

Inventory in Transit

 

Inventory in transit is stated at actual cost invoiced by the supplier at time of shipment.

Cost of Sales

 

At the time of sale, the Cost of Sales is computed at actual cost based on first-in, first-out accounting.  

Inventory consisted of:

 

December 31, 2016

 

December 31, 2015

Inventory – Raw Materials

$ -  

 

$ 30,886  

Inventory – Finished Goods

-  

 

29,018  

Total  

$ -  

 

$ 59,904  

 

At December 31, 2016, the Company recorded a reserve for impairment of inventory $36,097.   At December 31, 2015, the Company wrote off $90,878 of unused inventory of its Xtreme subsidiary.

 

 

13. Commitments and Contingencies  

 

Litigation

 

a) In April 2014, we were notified that a note holder disputes the balance of his note as recorded on the books of our company. The discrepancy arises from a question regarding expenses that the holder claims were paid on behalf of our company and subsequent payments that we recorded as payments against the note. We have no record of the expenses claimed to be due, and we are in negotiations to settle this matter. We have accrued $28,000 to cover the potential expenses and adjustments to accrued interest if the claim is substantiated. We believe it has properly accounted for all payments made to the individual and have provided documentation to him substantiating our position. 

 

b) In May 2014, the Company received notice that a complaint was filed in District Court, Clark County, NV alleging that the Company and various unnamed defendants are liable to a Mr. Renard Wiggins with regard to commissions and equity purportedly owed Mr. Wiggins, for services allegedly rendered in raising capital on behalf of the Company prior to the reverse merger between Alkame Holdings, Inc. (fka Pinacle Enterprises Inc.) and Alkame Water, Inc. in June 2013.  After initial review, the Company has filed for a dismissal of the case with the District Court, does not believe there is any validity to the claims of Mr. Wiggins, and intends to vigorously continue defending against these claims. As of December 31, 2015, all but two claims have been dismissed, and the Company is in court mandated settlement talks to determine if the remaining counts can be dismissed or will require further litigation. On November 15, 2016, the Company entered into a stipulated settlement agreement to issue 200,000,000 common shares in full and final settlement of this matter and all legal complaints are withdrawn.  In June 2018, the Company issued 92,780,388 shares of the agreed upon settlement. 

 

The Company may, from time to time, become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. The Company

 

F-31


is currently not aware of any such legal proceedings that it believes will have, individually or in the aggregate, a material adverse effect on its business, financial condition or operating results.

 

Commitments

In July 2015, the Company terminated the employment agreements with Keith Fuqua and Timm Ott.  Under the terms of the agreements, the Company will continue to make severance payments and provide health insurance through January 2016.

 

On January 19, 2016, the Company filed an 8-K announcing the formal termination of its January 22, 2015 MOU with Ready Made, Inc. due to the inability to come to mutually agreeable terms.

 

 

Material Agreements

 

Stock Purchase Definitive Agreement with Xtreme Technologies, Inc.

 

On April 21, 2014, we entered into a Stock Purchase Definitive Agreement (the “Agreement”) with Xtreme Technologies, Inc., an Idaho corporation (“Xtreme”). Pursuant to the terms of the Agreement, we agreed to acquire all of the issued and outstanding capital stock of Xtreme in exchange for certain consideration as set forth in the Agreement.

 

On January 16, 2015, the parties to the Agreement entered into an amendment (the “Amendment”) that changed, among other things, the Closing Date of the transaction.

 

On April 15, 2015, the parties to the Agreement entered into a second amendment (the “Second Amendment”) that changed, among other things, the 120-day time period to pay monetary consideration under the Agreement to 240 days after the Closing Date of the transaction.  

 

In accordance with the terms of the Agreement, the Amendment and the Second Amendment, we agreed to purchase all of the outstanding shares of Xtreme for the purchase price of $2,000,000, payable as follows:

 

A cash payment of $50,000 has been previously paid as a non-refundable deposit; 

The Closing Date is effective as of January 13, 2015; 

An additional cash payment of $525,000 shall be paid within two hundred and forty (240) days of the Closing Date, which, along with the initial $50,000 deposit, shall pay the obligations on Xtreme’s balance sheet;  

The balance of $1,425,000 shall be payable by the issuance of shares of the Company’s Series B Preferred Stock to be divided pro rata among the Company’s shareholders of record as of the Closing Date. The Series B Preferred Stock shall include an option to convert each share of Series B Preferred Stock into one share of the Company’s Common Stock. The Series B Preferred Stock shall be held in escrow along with the issued and outstanding shares of Xtreme’s capital stock pending the full payment of $525,000. As of the date of this report, the balance of $525,000 has been fully paid to Xtreme; and 

One of Xtreme’s previous officers and directors holds outstanding options to purchase up to 1,009,000 shares of Xtreme’s common stock at the price of $0.10 per share. At the Closing Date, pursuant to Idaho law, Xtreme shall notify this previous officer and director of his 30-day right to exercise any or all of his remaining options. If he elects to exercise any of his options within such 30-day period, the Company agrees to issue additional shares of Series B Preferred Stock in exchange for such Xtreme shares.  Xtreme notified the option holder and the 30-day period expired unanswered.  The options expired unexercised. 

 

 

 

 

 

 

 

 

F-32


The Amendment also requires that the Company guarantee the obligations on employment agreements for Xtreme’s key employees, namely, Keith Fuqua, Timm Ott and Casey Henry. The employment agreements with Messrs. Fuqua, Ott and Henry have the terms set forth in the following table.

 

 

Employee

Position

Term

Compensation

Commission

Benefits

Severance

Keith Fuqua

Operations Director

One year

$70,000 annually and annual bonus

5% on gross sales made to Walmart

Benefit plans

6 months’ severance for termination in certain instances; residual commissions for 1 year

Timm Ott

Sales and Marketing Director and Treasurer

One year

$2,700 per month salary and annual bonus

$1.00 per case of product sold

Benefit plans

6 months’ severance for termination in certain instances

Casey Henry

Manufacturing Director

One year

$4,350 per month and annual bonus

$1.00 per case of product sold

Benefit plans

6 months’ severance for termination in certain instances

 

In addition, after the Closing Date, Xtreme’s current officers and directors, namely, Jeffery J. Crandall, John N. Marcheso and Michael J. Bibin, shall continue to serve in that capacity until the $525,000 is paid in full. Our President and CEO, Robert K. Eakle and two (2) additional representatives of our company shall be appointed as directors of Xtreme and shall serve together with the other directors until the $525,000 is paid in full. In addition, Mr. Eakle shall be named as President and Chief Executive Officer of Xtreme. Until the $525,000 is paid in full, the officers and directors of Xtreme shall not make any material change in the company’s business and operations without unanimous consent of the directors. If the $525,000 is not paid in full within two hundred and forty (240) days of the Closing Date, as may be extended, then the appointments of Mr. Eakle and the other two representatives as interim officers and directors shall be terminated. Upon payment of $525,000 in full to Xtreme, all former officers and directors of Xtreme shall resign and full control of Xtreme shall be tendered to us. Provided that certain representations are accurate, Jeffery J. Crandall, John N. Marcheso and Michael J. Bibin shall be released by us and Xtreme from any liability as officers and directors of Xtreme for their fiduciary obligations occurring prior to the Closing Date.

 

We previously held a three-year limited exclusive distribution agreement with Xtreme for the consumer market. We were permitted to distribute the technologically enhanced bottled water in the consumer market in the United States, Canada and Mexico. As a result of the Agreement, Amendment, and Second Amendment, Xtreme became our wholly owned subsidiary and we acquired the patents on the proprietary process that we believe is the most technologically advanced in water treatment systems for complete hydration. We will now assume the operations of Xtreme and continue its business of distributing technologically enhanced bottled water.

 

Upon closing of the acquisition, we discovered that Xtreme was operating at a loss for the prior year and that it required a substantial cash infusion.  We have begun a program of upgrading the production line, reorganized personnel, and began an effort to increase sales of the division so that it returns to profitability as quickly as possible.

Our primary objective now is to introduce, promote, aggressively market and establish channels of distribution to sell our product to a wide range of consumers, first in the United States, Canada and Mexico, and then globally.

As of the date of this filing, the Company has closed down this division, and written the asset values off in their entirety.

 

F-33


Series C Convertible Preferred Stock to be issued:

During the year ended December 31, 2015, the Company committed to issue 1,425,000 shares of Series C Preferred stock valued at $1.00 per share as part of the Stock Purchase Agreement entered into with Xtreme Technologies, Inc

 

Employment Agreements  

On November 25, 2015, we entered into an employment agreement with our executive officer and director, Robert Eakle, (the “2015 Employment Agreement”).

Pursuant to the terms and conditions of the 2015 Employment Agreement with Mr. Eakle:

For the fiscal year ended December 31, 2015, we agreed to retain Mr. Eakle as Chief Executive Officer of our company and Mr. Eakle agreed to accept this senior officer position. 

The initial term of the Agreement is for a period of three years commencing January 1, 2015. 

Mr. Eakle shall receive an annual compensation of $120,000. 

Mr. Eakle received a one-time 1,000,000 shares of our newly created Series D Preferred Stock. 

In the event of insufficient liquidity, Mr. Eakle will be allowed to receive any unpaid and accrued portion of his cash compensation in the form of common stock or Series D Preferred Stock, as he may choose.  

On December 31, 2015, we entered into a consulting agreement with Kaufman & Associates Inc. (“Kaufman”) retroactive for the year ended 2015 (the “2015 Consulting Agreement”).

Pursuant to the terms and conditions of the 2015 Consulting Agreement with Kaufman:

For the fiscal year ended December 31, 2015, we agreed to retain Kaufman as a consultant and Kaufman agreed to act as a consultant. 

The initial term of the Agreement is for a period of three years commencing January 1, 2015. 

Kaufman shall receive an annual compensation of $120,000.  

Kaufman received a one-time 1,000,000 shares of our newly created Series D Preferred Stock. 

In the event of insufficient liquidity, Kaufman will be allowed to receive any unpaid and accrued portion of his cash compensation in the form of common stock or Series D Preferred Stock, as it may choose.  

The foregoing description of the 2015 Employment Agreement and 2015 Consulting Agreement does not purport to be complete and is qualified in its entirety by reference to the complete text of the agreements filed as Exhibits 10.1 and 10.2 to an 8K filed November 30, 2015 and incorporated herein by reference

High County Shrimp

On October 26, 2014, we acquired all 100% of the outstanding shares of High Country Shrimp Company (“HCS”), a Colorado LLC in exchange for one hundred thousand (100,000) shares of our common stock.  The shares are recorded as to be issued and priced at the closing price of the stock on October 27, 2014.  

 

It is expected that HCS will incorporate their patented technology for producing and selling high quality shrimp with our unique water treatment systems to create an intensive indoor aquaculture farming process.

 

The transaction is structured as a “triangular” merger with HCS becoming a wholly owned subsidiary of Alkame Holdings, Inc., however, after the year end, the principal of High Country Shrimp decided to abandon the current effort and asked if Alkame would enter a joint venture to support development of the technology through licensing of the water treatment system.  The Company will provide a limited license for development of the technology.

 

As of the date of this report, the Company has abandoned this transaction and recorded an impairment of $13,500.  

 

F-34


14. Concentration of credit risk  

 

Concentration of credit risk with respect to trade receivables is inherent as the Company begins the ramp up of its sales.  Long term, the Company does not foresee a concentrated credit risk associated with its trade receivables.  While repayment is dependent upon the financial stability of the various customers to which shipment takes place, major customers in the water industry are typically distributors or chain stores each with large, per shipment sales, but also with significant history and excellent credit.  In the year ended December 31, 2016, approximately 67% of sales came from seven customers.  The Company expects these percentages to drop significantly as it expands the number and territories covered by distributors and retailers.

 

 

15. Subsequent Events  

 

We have evaluated subsequent events through the date the consolidated financial statements were available to be issued, and did not have any material recognizable subsequent events, other than the following:

 

Stock Issuances

 

On January 4, 2017, the Company issued 56,100,000 common shares upon conversion of $28,050 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.0005 per share.

 

On January 19, 2017, the Company issued 58,900,000 common shares upon conversion of $70,680 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.0012 per share.

 

On January 25, 2017, the Company issued 121,212,121 common shares upon conversion of $20,000 of convertible debt.  The shares were issued at a price of $0.000165 per share.

 

On January 26, 2017, the Company issued 61,900,000 common shares upon conversion of $105,230 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.0017 per share.

 

On January 31, 2017, the Company issued 106,791,056 common shares upon conversion of $19,222 of convertible debt and accrued interest.  The shares were issued at a price of $0.00018 per share.

 

On February 1, 2017, the Company issued 60,000,000 common shares upon conversion of $10,800 of convertible debt.  The shares were issued at a price of $0.000185 per share.

 

On February 3, 2017, the Company issued 13,949,500 common shares upon conversion of $50,218 of accounts payable in connection with a settlement under the Section 3(a)10 of the Rules of the SEC.  The shares were issued at a price of $0.0036 per share.

 

On February 7, 2017, the Company issued 135,000,000 common shares upon conversion of $20,308 of convertible debt.  The shares were issued at a price of $0.00015 per share.

 

On February 7, 2017, the Company issued 124,642,333 common shares upon conversion of $22,436 of convertible debt and accrued interest.  The shares were issued at a price of $0.00018 per share.

 

On February 9, 2017, the Company issued 135,459,267 common shares upon conversion of $20,319 of convertible debt and accrued interest.  The shares were issued at a price of $0.00015 per share.

 

On February 10, 2017, the Company issued 45,279,174 common shares upon conversion of $2,717 of convertible debt.  The shares were issued at a price of $0.00006 per share.

 

F-35

On February 16, 2017, the Company issued 176,545,455 common shares upon conversion of $29,130 of convertible debt and accrued interest.  The shares were issued at a price of $0.000165 per share.

 

On February 16, 2017, the Company issued 70,000,000 common shares upon conversion of $7,000 of convertible debt and accrued interest.  The shares were issued at a price of $0.0001 per share.

 

On February 17, 2017, the Company issued 78,306,444 common shares upon conversion of $14,095 of convertible debt and accrued interest.  The shares were issued at a price of $0.00018 per share.

 

On February 17, 2017, the Company issued 164,931,500 common shares upon conversion of $29,688 of convertible debt and accrued interest.  The shares were issued at a price of $0.00018 per share.

 

On February 17, 2017, the Company issued 39,206,833 common shares upon conversion of $11,762 of convertible debt.  The shares were issued at a price of $0.0003 per share.

 

On February 17, 2017, the Company issued 86,936,364 common shares upon conversion of $28,689 of convertible debt and accrued interest.  The shares were issued at a price of $0.00033 per share.

 

On February 24, 2017, the Company issued 240,000,000 common shares upon conversion of $43,200 of convertible debt.  The shares were issued at a price of $0.00018 per share.

 

On February 24, 2017, the Company issued 125,000,000 common shares upon conversion of $22,500 of convertible debt.  The shares were issued at a price of $0.00018 per share.

 

On February 28, 2017, the Company issued 74,586,446 common shares upon conversion of $23,718 of convertible debt.  The shares were issued at a price of $0.000318 per share.

 

On March 1, 2017, the Company issued 108,085,525 common shares upon conversion of $40,100 of convertible debt and accrued interest.  The shares were issued at a price of $0.000371 per share.

 

On March 10, 2017, the Company issued 120,000,000 common shares upon conversion of $28,800 of convertible debt and accrued interest.  The shares were issued at a price of $0.00024 per share.

 

On March 13, 2017, the Company issued 159,978,301 common shares upon conversion of $33,915 of convertible debt and accrued interest.  The shares were issued at a price of $0.000212 per share.

 

On March 16, 2017, the Company issued 100,000,000 common shares upon conversion of $24,000 of accrued interest.  The shares were issued at a price of $0.00024 per share.

 

On March 22, 2017, the Company issued 131,344,669 common shares upon conversion of $27,845 of convertible debt and accrued interest.  The shares were issued at a price of $0.000212 per share.

 

On March 23, 2017, the Company issued 166,666,667 common shares upon conversion of $44,700 of accrued interest.  The shares were issued at a price of $0.000268 per share.

 

On May 19, 2017, the Company issued 171,500,000 common shares upon conversion of $44,590 of convertible debt and accrued interest.  The shares were issued at a price of $0.00026 per share.

 

On June 2, 2017, the Company issued 57,692,307 common shares upon conversion of $15,000 of convertible debt and accrued interest.  The shares were issued at a price of $0.00026 per share.

 

On June 5, 2017, the Company issued 171,153,846 common shares upon conversion of $44,500 of convertible debt and accrued interest.  The shares were issued at a price of $0.00026 per share.

 

F-36


On August 16, 2017, the Company issued 122,500,000 common shares upon conversion of $14,700 of convertible debt and accrued interest.  The shares were issued at a price of $0.00012 per share.

 

On February 22, 2018, the Company issued 215,000,000 common shares upon conversion of $21,500 of convertible debt and accrued interest.  The shares were issued at a price of $0.0001 per share.

 

On March 8, 2018, the Company issued 220,000,000 common shares upon conversion of $22,000 of convertible debt and accrued interest.  The shares were issued at a price of $0.0001 per share.

 

On March 23, 2018, the Company issued 135,000,000 common shares upon conversion of $13,500 of convertible debt and accrued interest.  The shares were issued at a price of $0.0001 per share.

 

On April 11, 2018, the Company issued 320,000,000 common shares upon conversion of $32,000 of convertible debt and accrued interest.  The shares were issued at a price of $0.0001 per share.

 

On May 8, 2018, the Company issued 55,000,000 common shares upon conversion of $5,500 of convertible debt and accrued interest.  The shares were issued at a price of $0.0001 per share.

 

On June 8, 2018, the Company issued 92,780,388 common shares in connection with a stipulated settlement agreement entered into by the Company in early 2017.  The shares were issued at a price of $0.0019 per share.

 

Convertible Debts:

 

On April 17, 2017, the Company entered into a Stock Purchase Agreement (the “SPA”) with an accredited investor group (the “Investor” or “Buyer”).  Under the terms of the SPA, the Investor will purchase up to $550,000 of convertible debentures in a series of four tranches. The first tranche will be in the amount of $220,000, with each of the three successive tranches in the amount of $110,000.  

 

Each note will be issued with a 10% Original Issue Discount (“OID”) such that the net amount received by the Company will be either $200,000 or $100,000 per debenture.  The convertible debentures are due and payable one year from date of issuance and will carry interest at a rate of 8% per annum from the date of issuance.  Each debenture will be convertible into common stock of the Company at the lower of (i) 70% of the lowest trading price of the Common Stock as reported on the OTCPK marketplace which the Company's shares are traded or any market upon which the Common Stock may be traded in the future ("Exchange"), during the twenty (20) trading days immediately preceding the closing date or (ii) 70% of the lowest trading price of the Common Stock as reported on the OTCPK marketplace which the Company's shares are traded or any market upon which the Common Stock may be traded in the future ("Exchange"), during the twenty 20 trading days immediately preceding the receipt of a notice of conversion.  

 

Subsequent funding’s after the second tranche are conditioned on the Company completing the filing of its audits within 59 days of the date of the first funding, and subsequent tranches will require completion of the remaining filings necessary to bring the Company current in its reporting obligations.  

 

Additionally, while the Notes are outstanding, the Company is prohibited from entering into any convertible debentures or 3(A)(10) financings with another party without prior written consent of the Buyer.

 

The Buyer has, for a period of 6 months from the sale of the first note purchased, to invest up to an additional $500,000, in one or more tranches, on the same terms as those in the first four notes being purchased.  

On October 17, 2017, the Company entered into a nine-month convertible debenture for $16,500 with an accredited institutional investor.  The debenture carries a 10% original issue discount, and interest at a rate of 8% per annum.  The debenture is convertible at 70% of the lowest trading price in the 20 trading days prior to conversion.

 

F-37

 

On October 25, 2017, the Company entered into a nine-month convertible debenture for $27,500 with an accredited institutional investor.  The debenture carries a 10% original issue discount, and interest at a rate of 8% per annum.  The debenture is convertible at 70% of the lowest trading price in the 20 trading days prior to conversion.

On October 30, 2017, the Company entered into a nine-month convertible debenture for $22,000 with an accredited institutional investor.  The debenture carries a 10% original issue discount, and interest at a rate of 8% per annum.  The debenture is convertible at 70% of the lowest trading price in the 20 trading days prior to conversion.

On November 5, 2017, the Company entered into a nine-month convertible debenture for $22,000 with an accredited institutional investor.  The debenture carries a 10% original issue discount, and interest at a rate of 8% per annum.  The debenture is convertible at 70% of the lowest trading price in the 20 trading days prior to conversion.

On November 9, 2017, the Company entered into a nine-month convertible debenture for $90,000 with an accredited institutional investor.  The debenture carries a 10% original issue discount, and interest at a rate of 8% per annum.  The debenture is convertible at 70% of the lowest trading price in the 20 trading days prior to conversion.

On December 31, 2017, the Company entered into a nine-month convertible debenture for $22,000 with an accredited institutional investor. The debenture carries a 10% original issue discount, and interest at a rate of 8% per annum. The debenture is convertible at the lower of (a) $0.0001; or (b) 70% of the lowest trading price in the 20 trading days prior to conversion.

On January 3, 2018, the Company entered into a nine-month convertible debenture for $30,000 with an accredited institutional investor.  The debenture carries a 10% original issue discount, and interest at a rate of 8% per annum.  The debenture is convertible at 70% of the lowest trading price in the 20 trading days prior to conversion.

On January 13, 2018, the Company entered into a nine-month convertible debenture for $22,000 with an accredited institutional investor.  The debenture carries a 10% original issue discount, and interest at a rate of 8% per annum.  The debenture is convertible at 70% of the lowest trading price in the 20 trading days prior to conversion.

On January 17, 2018, the Company entered into a nine-month convertible debenture for $16,500 with an accredited institutional investor. The debenture carries a 10% original issue discount, and interest at a rate of 8% per annum. The debenture is convertible at the lower of (a) $0.0002; or (b) 70% of the lowest trading price in the 20 trading days prior to conversion.

On January 25, 2018, the Company entered into a nine-month convertible debenture for $27,500 with an accredited institutional investor. The debenture carries a 10% original issue discount, and interest at a rate of 8% per annum. The debenture is convertible at the lower of (a) $0.0003; or (b) 70% of the lowest trading price in the 20 trading days prior to conversion.

On January 30, 2018, the Company entered into a nine-month convertible debenture for $22,000 with an accredited institutional investor. The debenture carries a 10% original issue discount, and interest at a rate of 8% per annum. The debenture is convertible at 70% of the lowest trading price in the 20 trading days prior to conversion.

On February 5, 2018, the Company entered into a nine-month convertible debenture for $22,000 with an accredited institutional investor. The debenture carries a 10% original issue discount, and interest at a rate of 8% per annum. The debenture is convertible at the lower of (a) $0.0003; or (b) 70% of the lowest trading price in the 20 trading days prior to conversion.

On February 9, 2018, the Company entered into a nine-month convertible debenture for $90,200 with an accredited institutional investor. The debenture carries a 10% original issue discount, and interest at a rate of 8% per annum. The debenture is convertible at the lower of (a) $0.0003; or (b) 70% of the lowest trading price in the 20 trading days prior to conversion.

F-38

On February 16, 2018, the Company entered into a nine-month convertible debenture for $55,000 with an accredited institutional investor.  The debenture carries a 10% original issue discount, and interest at a rate of 8% per annum.  The debenture is convertible at 70% of the lowest trading price in the 20 trading days prior to conversion.

On February 23, 2018, the Company entered into a nine-month convertible debenture for $55,000 with an accredited institutional investor.  The debenture carries a 10% original issue discount, and interest at a rate of 8% per annum.  The debenture is convertible at 70% of the lowest trading price in the 20 trading days prior to conversion.

On February 26, 2018, the Company entered into a nine-month convertible debenture for $55,000 with an accredited institutional investor.  The debenture carries a 10% original issue discount, and interest at a rate of 8% per annum.  The debenture is convertible at 70% of the lowest trading price in the 20 trading days prior to conversion.

On March 8, 2018, the Company entered into a nine-month convertible debenture for $55,000 with an accredited institutional investor.  The debenture carries a 10% original issue discount, and interest at a rate of 8% per annum.  The debenture is convertible at 70% of the lowest trading price in the 20 trading days prior to conversion.

On March 15, 2018, the Company entered into a nine-month convertible debenture for $22,000 with an accredited institutional investor.  The debenture carries a 10% original issue discount, and interest at a rate of 8% per annum.  The debenture is convertible at 70% of the lowest trading price in the 20 trading days prior to conversion.

On March 30, 2018, the Company entered into a 30-Day convertible debenture for $33,000 with an accredited institutional investor.  The debenture carries a 10% original issue discount, and interest at a rate of 8% per annum.  The debenture was repaid prior to 30-day periods expiration.  

On May 16, 2018, the Company entered into a one-month, secured note for $50,000 with an accredited investor.  The note carries 13.5% interest and was repaid prior to its due date.

On June 6, 2018, the Company entered into a one-month, secured note for $50,000 with an accredited investor.  The note carries 12.5% interest and is due July 6, 2018.  

On June 8, 2018, the Company entered into a nine-month convertible debenture for $55,000 with an accredited institutional investor.  The debenture carries a 10% original issue discount, and interest at a rate of 8% per annum.  The debenture is convertible at 70% of the lowest trading price in the 20 trading days prior to conversion.

Others:

On May 1, 2017, the Company entered into a five-year Commercial Sublease (the “Sublease”) with Bell Foods and Bell Northside, LLC.  Pursuant to the Sublease, the Property is approximately seventeen (17) acres and includes approximately twelve (12) acres of farm ground. On the remaining five (5) acres is where the production facility is located, and the company subleased a majority portion of that processing facility. A portion of the property has a food processing facility.  The Company is required to pay $7,000 per month under the Sublease, which increases to $10,000 per month after three months.

 

On the same date, the Company entered into an Equipment Lease Agreement (the “Equipment Lease”) with Bell Foods to use certain equipment located on the property located in the food processing facility for a nominal fee. A Letter Agreement that predated the Equipment Lease, but effective as of May 1, 2017, was designed to supplement the Equipment Lease with an assignment by Bell Foods of its account’s receivables, with the assumption by the Company of accounts payable, including a loan payable to Craig Bell in the sum of $150,000.  

 

Further under the Letter Agreement, Bell Foods was required to use the accounts receivable, prior to the effective date, to pay portions of the accounts payable. In the event there were insufficient funds to pay off the accounts payable, Craig Bell agreed to loan additional funds to Bell Foods, which would become part of the unpaid balance of the outstanding note.

 

F-39


Prior to the effective date, Bell Foods used approximately $60,438.76 in accounts receivables to retire $60,438.76 in accounts payables, namely $49,000.00 paid to the Craig Bell note. On the effective date, May 1, the remaining accounts receivable, valued at approximately $117,248.70, and remaining accounts payable, valued at approximately $48,797.46, were transferred to the Company and the Company released Bell Foods from all liability associated with the accounts payable.  The company retired the remaining balance of the Craig Bell note on May 22nd. As of July 31, 2017, the accounts payable was $169,722.96, with the accounts receivable at $178,158.10.

 

The Company also entered into a Wastewater Disposal Agreement, effective as of May 1, 2017, with Bell Foods, Jones Place, LLC (“Jones Place”) and Bell Farms, Inc.  This agreement concerns the right to use brine wastewater ponds that reside at the property. The Company executed this agreement to deliver wastewater to the ponds located on the property under the specifications mandated by the Oregon Department of Environmental Quality.

 

Prior to entering into these agreements, the Company had been searching for a larger facility for increased warehousing and productions space for its water products.  The Company was also interested in the property to diversify its water product line and possibly enter into the flavored beverages segment of the market for unique teas and health beverages.  The Company believes that the foregoing agreements will afford the Company a unique opportunity – to lease not only warehousing space, but also use the existing equipment and infrastructure to manufacture on a “hot fill” and “healthy beverage” production line, as well as install the Company’s bottling line, which due to added automation and redesigned layout, is expected to provide for more cost-efficient production.

 

As mentioned above, the Company received a discount on the first three months’ lease cost.  This was provided as an offset for removing or disposing of various manufacturing supplies left behind from Bell Foods’ production operations.

 

In the Company’s original Current Report on Form 8-K (May 8, 2017), the Company had indicated that the deal was structured as an assumption of the operations of Bell Foods, and with it significant revenue opportunities.  In fact, as stated in the Letter Agreement, the Company is simply assisting Bell Foods close out its outstanding payables.  The Company has chosen to employ several members of the previous staff that previously worked for Bell Foods in connection with the Company’s water business.

 

The Company’s main focus has always been in utilizing the patented water treatment technology for as many applications and market segments as possible, creating more revenue streams. Growing its co-packing and private label business opportunities, and utilizing its water technology whenever possible, should begin to grow substantially due to the new location and added capabilities the facility has. The Company may choose, in the future, to expand its water business with hot drinks and health beverages, which the new facility is capable of providing with added resources.

 

This assumption of operations may add approximately $1.5 million in annual revenue to Alkame.  In addition to the added revenue, all customers’ accounts, accounts payable and receivables, inventory, internet properties, and an extensive library of product formulations, along with the continuation to offer private label programs and customized co-packing solutions for a selected variety of specialty gourmet items.  Along with the acquisition brings the ownership and title to the product expansion product offerings of the brands: Everyday Gourmet Fine Foods, Everyday Organic Fine Foods, Mr. Jalapeno, and NutraBell Gourmet Fine Foods. 

 

On May 1, 2017, the Company entered into a purchase agreement to acquire the OmegaHemp brand and associated intellectual property consisting of, but not limited to, the application for the registration of the trademark name, logos, labels, artwork, web URL and associated domains, packaging configurations and promotional materials and formulations. The purchase price of $25,000 is payable over a period of twelve months from date of closing.

 

In April 2019, the Company entered into a settlement agreement with a vendor under which the Company has agreed to a payment schedule over a four-month period to liquidate the agree to balance of $45,000.  The Company has made the first payment, and so long as the remaining three payments are made in a timely manner, no further collection activity will occur.

 

In May 2019, the Company was made aware of a judgement totaling approximately $36,679 for past due invoices from a vendor.  The Company is contacting the attorney to make arrangements for the payment of the amounts due.

 

F-40


 

Item 9. Changes In and Disagreements with Accountants on Accounting and Financial Disclosure

 

None

 

Item 9A. Controls and Procedures

 

Disclosure Controls and Procedures

 

As required by Rule 13a-15 under the Securities Exchange Act of 1934, we have carried out an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this annual report, being December 31, 2016. This evaluation was carried out under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer.

 

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our company’s reports filed under the Securities Exchange Act of 1934 is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

 

Based upon that evaluation, including our Chief Executive Officer and Chief Financial Officer, we have concluded that our disclosure controls and procedures were not effective as of the end of the period covered by this annual report.

 

Management’s Report on Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934). Management has assessed the effectiveness of our internal control over financial reporting as of December 31, 2016 based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. As a result of this assessment, management concluded that, as of December 31, 2016, our internal control over financial reporting was not effective. Our management identified the following material weaknesses in our internal control over financial reporting, which are indicative of many small companies with small staff: (i) inadequate segregation of duties and effective risk assessment; and (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.

 

We have begun to take steps to enhance and improve the design of our internal control over financial reporting. During the period covered by this annual report on Form 10-K, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we have begun the implementation of the following changes during our fiscal year ending December 31, 2016: (i) appointed additional qualified personnel to address inadequate segregation of duties and ineffective risk management; and (ii) adopt sufficient written policies and procedures for accounting and financial reporting. The remediation efforts set out in (i) and (ii) are largely dependent upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.

 

Our internal control over financial reporting was not subject to attestation by our independent registered public accounting firm pursuant to the rules of the SEC that permit us, as an emerging growth company, to provide only management’s report in this annual report. 

 

71

Remediation of Material Weakness

 

With our subsequent acquisition of the Bell Foods and Beverages operations and facility, we have added a full-time bookkeeper to handle the majority of the day-to-day posting and administrative work in the office.  In early 2019, we added a second experiences bookkeeper to assist with catching up our delinquent workload and to work with our outsourced financial advisor to complete or delinquent reporting obligations.  While this may take several months to accomplish, we are well on our way to becoming current with all our reporting obligations.

 

Limitations on the Effectiveness of Internal Controls

 

Our management, including our Chief Executive Officer and our Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting are or will be capable of preventing or detecting all errors or all fraud. Any control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements, due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns may occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risk.

 

 

Changes in Internal Control

 

There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during our year ended December 31, 2016 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

Item 9B. Other Information

 

None

 

PART III

 

Item 10. Directors, Executive Officers and Corporate Governance

 

The following table contains information with respect to our current executive officers and directors:

 

Name

Age

Principal Positions With Us

Robert Eakle

45

President, Chief Executive Officer and Director

 

Robert Eakle is our President, Chief Executive Officer, and Director. Robert has dedicated the last six years pursuing his passion for alkaline waters. Mr. Eakle formed Alkame Water, Inc. on March 1, 2012.  From that point on, he had been the President, CEO and director of Alkame.  Prior to that, in 2008, Mr. Eakle formed US Beverages Service, LLC, and was the owner/manager of that company.

 

72

Term of Office

 

Our directors are appointed for a one-year term to hold office until the next annual general meeting of our shareholders or until removed from office in accordance with our bylaws. Our officers are appointed by our board of directors and hold office until removed by the board.

 

Family Relationships

 

There are no family relationships between or among the directors, executive officers or persons nominated or chosen by us to become directors or executive officers.

 

Involvement in Certain Legal Proceedings

 

During the past ten years, none of the following occurred with respect to a present or former director, executive officer, or employee: (1) any bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time; (2) any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offenses); (3) being subject to any order, judgment or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his or her involvement in any type of business, securities or banking activities; and (4) being found by a court of competent jurisdiction (in a civil action), the SEC or the Commodities Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended or vacated.

 

Committees of the Board

 

Our company currently does not have nominating, compensation or audit committees or committees performing similar functions nor does our company have a written nominating, compensation or audit committee charter. Our directors believe that it is not necessary to have such committees, at this time, because the functions of such committees can be adequately performed by the board of directors.

  

Our company does not have any defined policy or procedural requirements for shareholders to submit recommendations or nominations for directors. The board of directors believes that, given the stage of our development, a specific nominating policy would be premature and of little assistance until our business operations develop to a more advanced level. Our company does not currently have any specific or minimum criteria for the election of nominees to the board of directors and we do not have any specific process or procedure for evaluating such nominees. The board of directors will assess all candidates, whether submitted by management or shareholders, and make recommendations for election or appointment.

 

A shareholder who wishes to communicate with our board of directors may do so by directing a written request addressed to our CEO and director, Robert Eakle, at the address appearing on the first page of this annual report.

 

Code of Ethics

 

We have not adopted a Code of Ethics that applies our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions.

 

73

Item 11. Executive Compensation

 

The table below summarizes all compensation awarded to, earned by, or paid to our officers for all services rendered in all capacities to us for our fiscal years ended December 31, 2016 and 2015.

 

SUMMARY COMPENSATION TABLE

Name and principal position

Year

Salary ($)

Bonus

($)

 

Stock

Awards

($)

Option

Awards

($)

Non-Equity

Incentive Plan

Compensation

($)

Nonqualified

Deferred

Compensation

Earnings ($)

All Other

Compensation

($)

Total

($)

Robert Eakle

President, Chief Executive Officer, Chief Financial Officer, and Director

2016

2015

 

 

120,000

120,000

 

 

0

0

 

 

0

30,000

 

 

0

0

 

 

0

0

 

 

0

0

 

 

0

0

 

 

120,000

150,000

 

 

 

Narrative Disclosure to Summary Compensation Table  

On November 25, 2015, we entered into an employment agreement with our executive officer and director, Robert Eakle, retroactive for the year ended 2015 (the “2015 Employment Agreement”).

Pursuant to the terms and conditions of the 2015 Employment Agreement with Mr. Eakle:

For the fiscal year ended December 31, 2015, we agreed to retain Mr. Eakle as Chief Executive Officer of our company and Mr. Eakle agreed to accept this senior officer position. 

The initial term of the Agreement is for a period of three years commencing January 1, 2015. 

Mr. Eakle shall receive an annual compensation of $120,000. 

Mr. Eakle received a one-time 1,000,000 shares of our newly created Series D Preferred Stock. 

In the event of insufficient liquidity, Mr. Eakle will be allowed to receive any unpaid and accrued portion of his cash compensation in the form of common stock or Series D Preferred Stock, as he may choose.  

The foregoing description of the 2015 Employment Agreement does not purport to be complete and is qualified in its entirety by reference to the complete text of the agreements filed as Exhibit 10.1 to an 8K filed November 30, 2015 and incorporated herein by reference

On December 9, 2015, we issued 1,000,000 Series D Preferred shares to our CEO. The shares were issued at the market price of the common shares on the date of issuance multiplied by the number of common shares into which the Series D Preferred could convert or $0.03 per preferred share.

Outstanding Equity Awards at Fiscal Year-End

 

There were no unexercised options, stock that has not vested, and equity incentive plan awards for any officer or employee as of December 31, 2016 and 2015, respectively.

 

74


 

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 

The following table sets forth, as of May 10, 2019, certain information as to shares of our common stock, Series A Convertible Preferred Stock and Series B Convertible Preferred Stock owned by (i) each person known by us to beneficially own more than 5% of our outstanding common stock, (ii) each of our directors, and (iii) all of our executive officers and directors as a group.

 

Except as otherwise indicated, all shares are owned directly, and the shareholders listed possesses sole voting and investment power with respect to the shares shown. Unless otherwise indicated below, each entity or person listed below maintains an address of 3651 Lindell Road, Suite D # 356, Las Vegas, Nevada 89103.

 

 

Common Stock

 

Series A
Preferred Stock

 

Series B
Preferred Stock

 

Series D
Preferred Stock

Name and Address of Beneficial Owner

Number of Shares Owned (1)

 

Percent of Class (2)

 

Number of Shares Owned (1)

 

Percent of Class (2)

 

Number of Shares Owned
(1)

 

Percent of Class
(2)

 

Number of Shares Owned
(1)

 

Percent of Class
(2)

Robert Eakle (3) 

450,000

 

0.0008%

 

10,000,000

 

83.33%

 

46,412,964

 

70.97%

 

1,000,000

 

50.0%

All Directors and Executive Officers as a Group (1 person)

450,000

 

0.0008%

 

10,000,000

 

83.33%

 

46,412,964

 

70.97%

 

1,000,000

 

50.0%

5% Holders

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Kaufman & Associates Inc. (4)

500,000

 

0.0009%

 

2,000,000

 

16.67%

 

7,277,500

 

11.12%

 

1,000,000

 

50.0%

 

 

(1) Except as otherwise indicated, the persons named in this table have sole voting and investment power with respect to all shares of common stock shown as beneficially owned by them, subject to community property laws where applicable and to the information contained in the footnotes to this table.

 

(2) Pursuant to Rules 13d-3 and 13d-5 of the Exchange Act, beneficial ownership includes any shares as to which a shareholder has sole or shared voting power or investment power, and also any shares which the shareholder has the right to acquire within 60 days, including upon exercise of common shares purchase options or warrants. There are 5,500,000,000 shares of common stock, 12,000,000 shares of Series A Convertible Preferred Stock, 65,398,334 shares of Series B Preferred stock and 2,000,000 shares of Series A Convertible Preferred Stock issued and outstanding as of May 10, 2019 including securities exercisable or convertible into shares of Common Stock within sixty (60) days hereof for each stockholder.

 

(3) Includes 450,000 shares of common stock, 10,000,000 shares of Series A Convertible Stock that may be converted into 500,000,000 shares of common stock, 46,412,964 shares of Series B Preferred Stock that may be converted into 46,412,964 shares of common stock, and 1,000,000 shares of Series D Preferred Stock that may be converted into 10,000,000 shares of common stock.

 

(4) Includes 500,000 shares of common stock, 2,000,000 shares of Series A Convertible Stock that may be converted into 100,000,000 shares of common stock, 7,277,500 shares of Series B Preferred Stock that may be converted into 7,277,500 shares of common stock, and 1,000,000 shares of Series D Preferred Stock that may be converted into 10,000,000 shares of common stock.

 

75

 

Item 13. Certain Relationships and Related Transactions, and Director Independence

 

Other than the transactions described below and under the heading “Executive Compensation” (or with respect to which such information is omitted in accordance with SEC regulations), for the past two fiscal years there have not been, and there is not currently proposed, any transaction or series of similar transactions to which we were or will be a participant in which the amount involved exceeded or will exceed $120,000, and in which any director, executive officer, holder of 5% or more of any class of our capital stock or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest.

 

During the year ended December 31, 2016 and 2015, the Company received $0 and $22,967 respectively, in cash loans from its President, and made cash payments on these amounts owing totaling $10,324 and $0, respectively during the same periods.  

As of December 31, 2016, and 2015, the Company owes $16,132 and $26,456 respectively to its President.  The amounts owing are unsecured, non-interest bearing and due on demand.

As of December 31, 2016, and 2015, the Company owes its president $360,000 and $240,000, respectively, of accrued compensation.

On December 31, 2015, we entered into a consulting agreement with Kaufman & Associates Inc. (“Kaufman”) retroactive for the year ended 2015 (the “2015 Consulting Agreement”).

Pursuant to the terms and conditions of the 2015 Consulting Agreement with Kaufman:

For the fiscal year ended December 31, 2015, we agreed to retain Kaufman as a consultant and Kaufman agreed to act as a consultant. 

The initial term of the Agreement is for a period of three years commencing January 1, 2015. 

Kaufman shall receive an annual compensation of $120,000.  

Kaufman received a one-time 1,000,000 shares of our newly created Series D Preferred Stock. 

In the event of insufficient liquidity, Kaufman will be allowed to receive any unpaid and accrued portion of his cash compensation in the form of common stock or Series D Preferred Stock, as it may choose. 

The foregoing description of the 2015 Consulting Agreement does not purport to be complete and is qualified in its entirety by reference to the complete text of the agreement filed as Exhibit 10.2 to an 8K filed November 30, 2015 and incorporated herein by reference.

On December 9, 2015, we issued 1,000,000 Series D Preferred shares each to our consultant, Kaufman & Associates Inc.  The shares were issued at the market price of the common shares on the date of issuance multiplied by the number of common shares into which the Series D Preferred could convert or $0.03 per preferred share.

As of December 31, 2016, and 2015, the Company owes $307,270 and $213,480, respectively to Kaufman & Associates (holding more than 5% shares of the Company) in connection with a consulting agreement and included in accrued compensation on the balance sheet.

 

76

Item 14. Principal Accounting Fees and Services

 

The following table shows the fees that were billed for the audit and other services provided by RBSM LLP for the fiscal years ended December 31, 2016 and 2015.

 

Financial Statements for the Year Ended December 31,

Audit Services

Audit Related Fees

Tax Fees

Other Fees

2016

$ 40,000

$-

$-

$-

2015

$ 40,000

$-

$-

$-

 

Audit Fees  — This category includes the audit of our annual consolidated financial statements, review of consolidated financial statements included in our Quarterly Reports on Form 10-Q and services that are normally provided by the independent registered public accounting firm in connection with engagements for those fiscal years. This category also includes advice on audit and accounting matters that arose during, or as a result of, the audit or the review of interim financial statements.

 

Audit-Related Fees  — This category consists of assurance and related services by the independent registered public accounting firm that are reasonably related to the performance of the audit or review of our financial statements and are not reported above under “Audit Fees.” The services for the fees disclosed under this category include consultation regarding our correspondence with the Securities and Exchange Commission and other accounting consulting.

 

Tax Fees  — This category consists of professional services rendered by our independent registered public accounting firm for tax compliance and tax advice. The services for the fees disclosed under this category include tax return preparation and technical tax advice.

 

All Other Fees  — This category consists of fees for other miscellaneous items.

 

Our Board of Directors has adopted a procedure for pre-approval of all fees charged by our independent registered public accounting firm.  Under the procedure, the Board approves the engagement letter with respect to audit, tax and review services. Other fees are subject to pre-approval by the Board, or, in the period between meetings, by a designated member of Board. Any such approval by the designated member is disclosed to the entire Board at the next meeting.

 

77


 

PART IV

 

Item 15. Exhibits, Financial Statements Schedules

 

(a)

Financial Statements and Schedules

 

The following consolidated financial statements and schedules listed below are included in this Form 10-K.

 

Financial Statements (See Item 8)

 

(b)

Exhibits

 

 

Exhibit Number

Description

3.1

Articles of Incorporation, as amended (1)

3.2

Certificate of Amendment (2)

3.3

Certificate of Change (2)

3.4

Certificate of Amendment (3)

3.5

Certificate of Designation (3)

3.6

Certificate of Designation (3)

3.7

Bylaws, as amended (1)

10.1

Stock Purchase Definitive Agreement (4)

10.1

Convertible debenture dated August 6, 2014 (5)

10.2

Convertible debenture dated August 6, 2014

10.3

Convertible debenture dated August 11, 2014 (5)

10.4

Agreement and Plan of Merger (6)

10.5

Retroactive Employment Agreement (7)

10.6

Retroactive Consulting Agreement (7)

10.7

Settlement Agreement and Stipulation (8)

10.8

Amendment to Stock Purchase Definitive Agreement (9)

10.9

Memorandum of Understanding Joint Venture (10)

10.10

Amendment to Stock Purchase Definitive Agreement (11)

10.11

Convertible debenture dated September 4, 2014

10.12

Convertible debenture dated September 5, 2014

10.13

Convertible debenture dated September 11, 2014

10.14

Convertible debenture dated October 24, 2014

10.15

Convertible debenture dated October 27, 2014

10.16

Convertible debenture dated October 29, 2014

10.17

Convertible debenture dated November 12, 2014

10.18

Convertible debenture dated December 16, 2014

10.19

Convertible debenture dated January 7, 2015

10.20

Convertible debenture dated February 20, 2015

31.1

Certification of Chief Executive Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

32.1

Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

Incorporated by reference to the Registration Statement on Form S-1 filed on June 21, 2011; also incorporated by reference to the Current Report on Form 8-K filed on October 29, 2010. 

Incorporated by reference to the Form 8-K filed on January 8, 2014 

Incorporated by reference to the Form 8-K filed on January 27, 2014 

Incorporated by reference to the Form 8-K filed on April 22, 2014 

Incorporated by reference to the Form 8-K filed on August 22, 2014 

 

78


? Incorporated by reference to the Form 8-K filed on November 4, 2014 

Incorporated by reference to the Form 8-K filed on January 7, 2015 

Incorporated by reference to the Form 8-K filed on January 13, 2015 

Incorporated by reference to the Form 8-K filed on January 20, 2015 

Incorporated by reference to the Form 8-K filed on January 26, 2015 

Incorporated by reference to the Form 8-K filed on June 9, 2015